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ABSTRACT OF THE DISSERTATION 
 
Viral Load Tests among  
People Living with Human Immunodeficiency Virus on Antiretroviral Therapy  
in Wenshan Prefecture, Yunnan Province of China 
 
by 
 
Youran Xu 
Doctor of Philosophy in Epidemiology 
University of California, Los Angeles, 2019 
Professor Roger Detels, Chair 
 
 
 
Background 
China has made great achievements in antiretroviral therapy (ART) among people living with 
HIV (PLWH), however, there is still a gap with the 90-90-90 targets, especially in rural areas. 
This study investigated three topics about the centralized viral load (VL) testing in Wenshan, 
China, including the coverage and timeliness of VL tests, the turnaround time (TAT) of VL tests, 
and factors associated with sustained viral suppression (SVS).  
 
 
iii 
 
Methods 
To address the three topics, three clinic-based studies were conducted respectively. First, a 
retrospective cohort study was conducted among 815 PLWH who initiated ART from 2015 to 
2016. Second, a sequential explanatory mixed-method study was conducted: (1) 2 892 VL tests 
performed in 2018 were reviewed; (2) in-depth interviews were conducted among 11 healthcare 
providers. Third, a questionnaire survey was conducted among 264 PLWH. 
 
Results  
First, in Wenshan, the cumulative VL testing rates (%) at 12, 18, and 24 months after ART 
initiation were 58.5%, 78.1%, and 93.0%, respectively. Patients who had healthier baseline status 
[adjusted hazard ratio (aHR)=1.40, 95% confidence interval (95%CI)=1.18-1.65] were more 
likely to undergo VL tests timely. On the contrary, patients who lived far away from ART sites 
(aHR=0.70, 95%CI=0.59-0.83) had delayed VL tests. Second, the median VL testing TAT was 
54 days (IQR: 36, 92). Factors associated with prolonged TAT mainly included the annual 
urban-to-rural labor migration, the shortage of healthcare professionals and lab technicians, 
limited VL testing instruments, and the immature reagent procurement system and testing results 
reporting system. Third, 61.0% (n=161) of the PLWH who participated in the survey had 
achieved SVS. A total of 58.3% (n=154) participants reported they had ever proactively asked 
about VL testing results and they were more likely to achieve SVS [adjusted odds ratio 
(aOR)=3.08, 95%CI=1.52-6.26)]. Other factors associated with SVS included baseline CD4 
count, VL-related knowledge, support from non-governmental organizations (NGO), age, and 
time interval from HIV diagnosis to ART initiation. 
 
iv 
 
Conclusions 
To achieve the 90-90-90 targets, the VL testing in rural China should be improved by combining 
the efforts of PLWH, local healthcare providers, NGO staff, and healthcare policymakers at all 
levels of government. 
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Chapter 1. Introduction 
1.1 Global HIV/AIDS epidemic  
Acquired Immune Deficiency Syndrome (AIDS) was first recognized as a new disease in the 
early 1980s and then spread rapidly all over the world
1–4
. The total number of people living with 
HIV (PLWH) has been continuously increased. By 2018, there had been 38 million PLWH 
globally, with 68% in sub-Saharan Africa and 16% in Asia and the Pacific
5
. Despite the growing 
total number of PLWH, the newly diagnosed HIV-infected cases have been steadily decreased 
year by year since the second half of the 1990s
5,6
. There were 1.7 million new HIV infections in 
2018, which had been reduced by 40% since the peak in 1997
5
. In addition, HIV-related 
mortality has continuously decreased since the implementation and scale-up of antiretroviral 
therapy (ART)
7–9
. The global estimated number of HIV-related death in 2018 was 770 000, 
which had decreased by 57% compared with a peak of 1.8 million HIV-related deaths in 2005
5,7
. 
 
1.2 Progress towards UNAIDS ’90-90-90’ targets  
To end the AIDS epidemic, ambitious 90-90-90 targets were established by the Joint United 
Nations Programme on HIV/AIDS (UNAIDS) in 2014. The targets required: (1) 90% of all 
PLWH will be diagnosed by 2020, (2) 90% of all diagnosed PLWH will receive sustained ART 
by 2020; (3) 90% of all PLWH receiving ART will have viral suppression by 2020
10
. It is 
estimated that by achieving the 90-90-90 targets, 28 million total new infections and 21 million 
AIDS-related deaths will be averted during 2015-2030, and the global AIDS epidemic can be 
ended by 2030
10–12
. By the end of 2016, remarkable progress had been made towards the 90-90-
90 targets: 70% of PLWH were diagnosed, 77% of diagnosed PLWH were receiving ART, and 
2 
 
82% PLWH on ART achieved viral suppression
13
. In Asia and the Pacific, where China is 
located, the three key numbers of the 90-90-90 targets were 71%, 66% and 83%, respectively
13
. 
 
In 2018, there were 23.3 million PLWH receiving ART, and the global ART coverage rate (%) 
reached over 60% among all PLWH, which increased by 150% compared to that in 2010
14
. In 
Asia and the Pacific, around 3.2 million PLWH were receiving ART in 2018, making the ART 
coverage rate reach 54%
14
. An important reason for ART coverage increasing is that the criteria 
for ART initiation have been modified a few times. As early as 2002, the World Health 
Organization ( WHO) guidelines recommended that only the patients with clinical HIV disease 
(WHO stage III or stage IV) or CD4<200/μL should initiate ART15. In 2010 and 2013, the 
criteria for ART initiation were adjusted to CD4<350/μL and CD4<500/μL, respectively16,17. 
Recently, important studies
18–20
 showed that initiating ART at a CD4 count level higher than 
500/μL was significantly associated with better virological outcomes and less AIDS-related 
events, hence, the WHO guidelines recommended to start ART immediately after HIV diagnosis 
regardless of CD4 count
21
. 
 
After ART initiation, it is necessary to routinely monitor the treatment response. Viral load (VL) 
is the most important indicator of HIV disease progression and ART response
22–25
. Routine VL 
testing should be performed at 6 months and 12 months after ART initiation, and then at least 
every 12 months thereafter, so that the virological failure (two successive VL>1 000 copies/mL 
within a 3-months interval) can be detected timely
21
. Among the PLWH receiving HIV clinical 
care and have undergone VL tests, good virological outcomes are observed in low- and mid-
income countries (LMIC). A study conducted in rural east Africa
26
 reported that 90% of PLWH 
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treated had viral suppression (VL<500 copies/mL). However, there is still a gap between VL 
testing demand and VL testing coverage in LMICs. In sub-Saharan Africa, more than 6 million 
PLWH on ART do not have access to VL testing
27
. 
 
1.3 HIV/AIDS epidemic and ART response in China 
 The HIV virus entered China in the mid-1980s, and the first AIDS outbreak occurred in 1989 
among 146 injection drug users (IDU) in Yunnan Province, which bordered Myanmar, Laos, and 
Vietnam and was near the "Golden Triangle"
28
. The HIV epidemic then spread from Yunnan 
Province to other parts of China through the drug distribution channels and the IDUs’ sexual 
partners and children
29
. In the mid-1990s, the second AIDS outbreak occurred among the 
commercial plasma donors in east-central provinces
29,30
. By 1998, HIV had reached all the 31 
provinces of mainland China
31
. After entering the 21
st
 century, the total numbers of PLWH and 
the number of newly diagnosed HIV cases have kept growing year by year (Figure 1.1)
32–38
. In 
2017, there were 134 512 newly reported HIV cases and brought the total number of PLWH to 
758 610, which increased by 150% and 110% compared to those in 2010, respectively
32,37,38
. The 
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number of all-cause death among PLWH in 2017 was 26 787, which only increased by 41% 
compared to the number in 2010
32,38
.  
 
Although the national HIV prevalence remains low (<0.1%), the distribution of PLWH in China 
is unbalanced. By 2014, three provinces (Yunnan, Sichuan, and Guangxi) had the highest HIV 
prevalence, and twelve provinces (Yunnan, Sichuan, Guangxi, Henan, Guangdong, Xinjiang, 
Chongqing, Guizhou, Hunan, Zhejiang, Jiangsu, and Beijing) had contributed more than 83% of 
the total HIV cases in the country
34
. IDU was once the most serious HIV transmission route 
before 2006, however, the proportion of sexual transmission had increased fast since 2005 
(Figure 1.2)
39
. Currently, over 90% of new HIV cases are transmitted sexually. In 2016, 67.1% 
(N=83533) of all newly diagnosed HIV cases were transmitted by heterosexual contact and 
27.6% (N=34 399) transmitted among men who have sex with men (MSM)
36
. 
 
5 
 
China’s National Free Antiretroviral Therapy Program (NFATP) was initiated among former 
plasma donors as a pilot project in 2002 and was officially launched in July 2005
39–41
. Free ART 
medications and HIV-related laboratory tests are provided to all eligible PLWH. In resource-
limited settings, WHO recommends a public-health approach to provide ART, which means that 
only simplified and standardized first- and second-line ART regimen combinations are routinely 
provided
42
. Currently, six first-line ART medications and one second-line ART medication are 
provided for free in China, including zidovudine (AZT), lamivudine (3TC), tenofovir (TDF), 
efavirenz (EFV), nevirapine (NVP), abacavir (ABC), and lopinavir/ritonavir (LPV/r) (LPV/r is 
used in the second-line ART)
43
. The latest ART implementation policy in China requires 
initiating first-line ART as soon as possible after HIV diagnosis regardless of CD4 cell count
21,43
. 
To monitor the ART response and detect treatment failure timely, routine VL tests and CD4 tests 
should be performed at least once a year. PLWH who fail the first-line ART can be considered to 
switch to a second-line ART regimen. By the end of 2017, the average ART coverage in China 
was over 80%
44
. National cohort studies
45,46
 reported that the rates of viral suppression (VL<400 
copies/mL) ranged from 89% to 91% among PLWH receiving ART.  
 
1.4 VL and VL tests 
VL is the preferred approach to monitor ART response and detect treatment failure. The 
definition of virological failure varies in different guidelines. In some well-resourced settings, a 
strict approach to define virological failure is VL>50 copies/mL
47
. Instead, the WHO guideline, 
which is usually applied in LMICs, defines the virological failure as two consecutive VL>1 000 
copies/mL within a 3-month interval with adherence support between the two measurements
21
. 
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High HIV viral load is significantly associated with early progression to AIDS, higher mortality, 
slower viral suppression, and higher HIV transmission rate
48-49
.  
 
The assays for quantification of HIV VL require very elaborate lab infrastructure, such as 
separate rooms for different test processes, temperature control, continuous power, and water and 
minimal dust
50,51
. Generally, plasma samples, which are obtained after venous blood collection 
and centrifugation, are used in the VL testing. Viral load assays can be divided into nucleic 
acids-based test (NAT) and non-acids-based test (non-NAT) technologies (Figure 1.3)
50
. The 
NAT technologies can directly detect and quantify HIV viral RNA, whereas, the non-NAT 
technologies detect and quantify HIV viral proteins
50,52
. Generally, there are three steps for VL 
assays with NAT technologies
50,51
. The first step or pre-amplification step includes sample 
preparation and nucleic acid extraction. The second step is nucleic acid amplification since the 
volume of nucleic acids is generally too low to be detected directly. The two main amplification 
methods for VL detection are target amplification and signal amplification. The target 
amplification can synthesize more “target nucleic acids” so that even very low-level nucleic 
acids can be detected. Target amplification mainly includes reverse transcription-polymerase 
chain reaction (RT-PCR) (e.g. Abbott RealTime and Roche COBAS) and nucleic acid sequence-
based amplification (NASBA) (e.g. bioMerieux NucliSENS EasyQ). In the signal amplification, 
large amounts of signals, which can be detected in the detection process, are attached to the 
original target nucleic acids. One commonly used technique of signal amplification is branched-
chain DNA (bDNA) (e.g. Siemens Versant
TM
). The third step of VL testing is the detection and 
quantification of amplified products or amplified signals. The non-NAT-based technologies 
7 
 
detect and quantify HIV-specific enzymes and proteins, including reverse transcriptase and p24 
antigen
50,52
.  
 
 
1.5  VL tests in LMICs 
VL testing needs high-quality infrastructure, sophisticated laboratory equipment, and well-
trained technicians
50,53
. In some real-world settings of LMICs, VL testing assays are only  
centralized in the city- or higher level laboratories, hence, centralized laboratory-based 
approaches are used for VL tests (Figure 1.4)
54
. PLWH who are retained in ART need to undergo 
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routine VL tests. Generally, they can visit local ART sites to donate VL testing blood samples. 
The samples are processed and temporarily stored in the local ART sites. Different local ART 
sites send blood samples to the same central VL laboratory periodically for VL testing. The 
technicians in the laboratory are in charge of performing VL tests, and then return the testing 
reports to the original ART sites. After receiving the reports, the healthcare providers in local 
ART sites can implement clinical interventions according to the reports and inform PLWH of the 
VL results. However, in some real-world settings, because of a shortage of healthcare providers 
and a lack of physician-patient communication, some patients cannot be informed of VL testing 
results until the next routine ART follow-up visits. Hence, some patients may tend to take the 
initiative to ask about VL testing results before patient notifications.  
9 
 
 
 
The time interval between VL blood sample collection and receipt of testing reports by the ART 
sites is defined as turnaround time (TAT) of the VL test. Specifically, the pre-test TAT refers to 
the time interval between blood sample collection and VL testing, and the post-time TAT refers 
to the time interval between VL testing and receipt of VL results by local ART sites (Figure 1.4). 
The TAT varies considerably among different countries. Studies in well-resourced settings 
reported the median VL testing TATs ranging from 1 to 8 days
55–57
. A study conducted in seven 
Sub-Saharan countries reported that the mean TAT in each country ranged from 3 days to 50 
days, and the mean TATs in five of the seven countries were close to or longer than 1 month
58,59
. 
Factors associated with prolonged TAT in LMICs are various. The pre-test TAT can be 
influenced by weak health and laboratory systems, incomplete sample referral network, and a 
10 
 
shortage of trained staff; and the post-test TAT is mainly influenced by immature results 
reporting systems
27,58,60–62
. Prolonged TAT results in delayed detection of treatment failure, 
which further leads to delayed clinical interventions among PLWH with treatment failure. 
Staying at an unsuppressed VL level for a long time is associated with higher mortality rates, 
more opportunistic infections, and higher HIV transmission rates
63–67
.  
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1.6 VL tests in China 
The general HIV care cascade in China is shown in Figure 1.5
43,68–70
. When a patient has positive 
results in both the first and the second HIV screenings and the HIV confirmatory test, he/she will 
be diagnosed as HIV infection and should initiate lifelong ART regardless of CD4 cell count
21
 
(step ①-⑤). After ART initiation, PLWH go on follow-up visits to local ART sites every three 
or four months for a refill of ART medications and to undergo laboratory tests. Some patients are 
dead or lost to follow-up (LTFU) during early ART. A nationwide cohort study
46
 of the Chinese 
PLWH reported that on average only 84% of patients were retained in ART for longer than 6 
months. Among those who have been retained in ART for longer than 6 months, VL tests will be 
performed to evaluate the treatment response (step ⑥-⑦). According to WHO guidelines and 
current Chinese standard practices, the first VL test is usually performed between 6 months and 
12 months after ART initiation
21,43
. Based on the Chinese ART guidelines, the viral suppression 
or virally suppressed is defined as VL<20 copies/mL or undetectable VL and the virological 
failure is defined as two successive VL>400 copies/mL, which are stricter than the definitions 
recommended by WHO (step ⑦-⑨)21,43.  
 
VL testing has been provided in China since 2006 and scaled up since 2008
71
. By 2015, there 
were about 4 000 healthcare facilities providing ART service around the country, however, only 
181 laboratories qualified to perform VL tests
34,72
. In addition, the VL testing laboratories are 
usually located in the capital region of a city or a province. Hence, the centralized laboratory-
based strategy is used for VL tests in China, especially in remote and rural areas. A nationwide 
serial cross-sectional study among Chinese PLWH
46
 reported the coverage of annual VL testing 
12 
 
among PLWH retained in care had increased from 50% in 2009 to 84% in 2015. However, a 
cohort study
73
 in rural China reported only 68% of PLWH had VL tests in their first year of 
ART. The VL testing TAT in rural China may vary from several weeks to months, however, 
there has been little published data about this issue. Studies
45,46
 reported that the average viral 
suppression (VL<400 copies/mL) rate among PLWH receiving sustained ART in China had 
approximately reached 90%. 
 
1.7 Study location: Wenshan Prefecture, Yunnan Province 
To investigate the centralized VL testing among PLWH in rural China, Wenshan Prefecture in 
Yunnan Province was selected as the study location. Yunnan Province is located in Southwest 
China and borders the countries Vietnam, Laos, and Myanmar. In 2018, the gross domestic 
product (GDP) of Yunnan was about 250 billion US dollars, ranking the 20
th
 of the 31 provinces 
in mainland China
74
. Yunnan had a population of 48 million at the end of 2017, among which 
53.3% are living in the rural areas
74
. The earliest HIV infected cases in China appeared among 
the IDUs in the border areas of Yunnan Province in the late 1980s
28
. By 1998, the HIV infection 
had spread from Yunnan Province to all other provinces of mainland China
31
. Currently, Yunnan 
is one of the provinces with the most serious HIV/AIDS epidemic and which pioneered ART 
implementation
34,75
. The cumulative number of PLWH in Yunnan accounted for 21% of the total 
number in China
76
. The main HIV transmission route has changed from injection drug use  to 
heterosexual contact
76,77
, which accounted for over 80% of newly diagnosed cases
75
. By the end 
of 2016, twenty-two laboratories in Yunnan were capable of VL testing
78
. 
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Wenshan Zhuang and Miao Autonomous Prefecture (“Wenshan” or “Wenshan Prefecture” for 
short) is located in the eastern mountainous region of Yunnan Province. The total population of 
Wenshan was about 3.6 million by 2017, among which 61% were living in rural areas
78,79
. The 
GDP per capita of Wenshan in 2017 was about 3 400 US dollars, which was 35% and 62% lower 
than the provincial and national averages, respectively
79–81
. Han ethnicity, China’s main 
ethnicity, only accounted for 42.0% of the Wenshan population; Zhuang, Miao, Yi, and other 
ethnic minorities accounted for 58.0%
79
. Wenshan is one of the regions with the largest number 
of PLWH within the province
82
. The number of PLWH receiving ART in 2017 was about 8 900. 
Nine county-level facilities and one prefecture-level facility provide ART and laboratory tests to 
all PLWH in the prefecture. However, only one central laboratory is eligible to perform VL tests 
in this prefecture.  
 
1.8 Study aims 
The third 90-90-90 target, which required 90% of PLWH receiving ART to achieve viral 
suppression, was focused on in this dissertation. Three topics during the process of centralized 
VL testing in rural China were investigated. The first topic was the coverage of timely VL tests 
among PLWH receiving ART; the second topic was the TAT of the centralized VL testing; the 
third topic was the association between active concern for VL testing results and the long-term 
virological outcomes, i.e. SVS. 
 
The specific aims of this study included: 
(1) To assess the coverage and timeliness of VL test and identify factors associated with delayed 
VL testing; 
14 
 
(2) To investigate the current VL testing TAT under the centralized testing strategy in rural 
China and identify factors associated with prolonged TAT. 
(3) To examine whether PLWH's active concern for VL testing results is associated with their 
SVS status and identify other factors associated with SVS.  
(4)  To provide suggestions for improving VL testing service and achieving 90-90-90 targets in 
rural China 
 
1.9 Summary of study methods 
Three ART sites and the only central VL testing laboratory in Wenshan Prefecture were selected 
as the study sites of our study. As shown in Figure 1.6, topic 1 (the coverage and timeliness of 
VL test) only involved the process of VL blood sample collection; topic 2 (VL testing TAT) 
involved all processes from blood sample collection to receipt of VL testing reports; topic 3 
(association between active concern for VL testing results and SVS) involved the process of 
patient notification. To address the three topics, three studies were conducted in the study sites. 
 
Study 1: 
Parts of PLWH could not undergo VL tests timely after ART initiation. To understand the 
coverage and timeliness of VL testing and identify factors associated with timely VL tests, a 
clinic-based retrospective cohort study was conducted among PLWH who initiated ART from 
2015 and 2016 in the three ART sites. Each participant was followed up from ART initiation to 
the date of first valid VL test, death, loss to follow-up (LTFU), transferring to other ART 
facilities or Dec 31, 2018, whichever came first. Basic characteristics were extracted from 
medical records. A survey was conducted among a subset of PLWH to supplement more detailed 
15 
 
information. The cumulative rate (%) of VL testing at 12, 18 and 24 months after ART initiation 
was calculated. Cox proportional hazard models were used to identify factors associated with the 
time of VL testing. 
 
 
 
 
Study 2: 
The VL testing TAT in rural China was prolonged. To investigate the TAT of centralized VL 
testing in rural settings, a sequential explanatory mixed-method study was conducted in the three 
ART sites and the central VL testing laboratory. The study contained a quantitative phase and a 
subsequent qualitative phase. In the quantitative phase, individual-level TAT was calculated for 
Figure 1.6 Summary of the three sub-study topics and the main data sources 
PLWH: people living with HIV; ART: antiretroviral therapy; VL: viral load; TAT: turnaround time; 
SVS: sustained viral suppression. Dropout was defined as loss to follow-up or discontinuation of ART  
16 
 
all VL blood samples collected in 2018. In the qualitative phase, in-depth interviews were 
conducted among healthcare providers in the ART sites and technicians in the central VL testing 
laboratory to identify factors associated with prolonged TAT. 
 
Study 3: 
Because of the prolonged TAT and shortages of healthcare providers, some PLWH could not be 
informed of the VL testing results until long after the VL blood sample collection, so that some 
of the patients tend to take the initiative to ask about the results before patient notification. To 
investigate whether active concern for VL testing results is associated with SVS, a clinic-based 
study was conducted in the three ART sites. PLWH who initiated ART during 2015 and 2016 in 
these three facilities were recruited to participate in a survey during Jan to Mar in 2019, which 
collected information about socio-demographic characteristics, VL testing experience, VL-
related knowledge, and family/social support using structured questionnaire. In addition, clinical 
characteristics and VL testing results were extracted from medical records. The rates (%) of viral 
suppression and SVS at the end of 2018 were calculated. Logistic regressions were conducted to 
investigate the association between actively asking about VL testing results and SVS, and to 
identify other factors associated with SVS. 
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Chapter 2: Timeliness of viral load tests among people living with HIV on 
antiretroviral therapy in Wenshan, China 
 
Abstract 
Objective: To understand the coverage and timeliness of viral load (VL) testing and identify 
factors associated with the timing of VL tests among people living with HIV (PLWH) in 
Wenshan Prefecture, Yunnan Province of China. 
 
Methods: A clinic-based retrospective cohort study was conducted among PLWH who initiated 
ART between Jan 1, 2015 and Dec 31, 2016 in Wenshan. Each participant was followed up from 
ART initiation to the date of the first valid VL test, death, loss to follow-up (LTFU), transferring 
to other ART facilities or Dec 31, 2018, whichever came first. Basic characteristics were 
extracted from medical records. A survey was conducted among a subset of PLWH to 
supplement more detailed information. The cumulative rate (%) of VL testing at 12, 18 and 24 
months after ART initiation was calculated. Cox proportional hazard models were used to 
identify factors associated with VL testing timing.  
 
Results: A total of 815 PLWH (source cohort) were recruited, among whom 264 (survey cohort) 
participated in a survey to collect additional information. In the source cohort, the median age 
was 42 years (IQR: 32-51), and 60.3% were male. About 94.5% PLWH reported they were 
infected with HIV through heterosexual contacts. The median CD4 cell count at ART initiation 
was 316/μL (IQR: 199-447). The cumulative VL testing rates (%) at 12, 18, and 24 months of 
ART were 58.5%, 78.1%, and 93.0%, respectively. Factors associated with early VL testing 
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included being older than 45 years (45-60 years: aHR=1.23, CI=1.03-1.48; >60 years: 
aHR=1.34, CI=1.07-1.70), WHO stage I & II at ART initiating (aHR=1.40, CI=1.18-1.65), 
initiating ART in 2016 (aHR=1.32, CI=1.14-1.53) and receiving ART at study Site C 
(aHR=2.20, CI=1.87-2.60). Additionally, multivariate analyses in the survey population (n=264) 
showed that living farther than 2-hours drive from the ART site (aHR=0.70, CI=0.59-0.83) and 
had a permanent job (aHR=0.71, CI=0.56-0.90) were associated with undergoing VL testing late. 
 
Conclusions: To improve VL testing timeliness in rural areas, PLWH who are young, live far 
away from ART facilities, and are at advanced WHO clinical stage should be targeted. HIV 
health service decentralization in remote rural areas is highly recommended. Efforts of patients, 
health service providers, governments and non-governmental organizations (NGOs) should be 
coordinated. 
 
Keywords: HIV/AIDS, antiretroviral therapy, viral load test, timeliness 
 
Introduction 
Viral load (VL) is the most important indicator of disease progression in HIV infection
1,2
. To 
monitor treatment response, VL should be routinely tested on people living with HIV (PLWH) 
after initiating antiretroviral therapy (ART)
3
. VL test can provide early detection of virologic 
failure and prompt timely adherence counseling and regimen switching for patients with 
unsuppressed VL
4–7
. The Joint United Nations Programme on HIV/AIDS (UNAIDS) established 
90-90-90 targets for ending the AIDS epidemic, which required 90% of PLWH on ART to 
achieve viral suppression
8
. One of the prerequisites for those targets was universal access to VL 
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testing. However, the gap between VL testing demand and VL testing coverage in recourse-
limited settings has still been huge. In sub-Saharan Africa, more than 6 million PLWH on ART 
do not have access to VL testing
7
.  
 
VL testing has been scaled up in China since 2008
9
. By 2015, there were 181 laboratories 
qualified to perform VL tests, covering all provinces across the country
10,11. China’s National 
Free ART Program (NFATP) provides free VL tests once a year to all PLWH after 6-month 
continuous ART
12,13
. Patients go on follow-up visits to ART clinics every three or four months 
for a refill of ART medications and to undergo laboratory testing. A nationwide serial cross-
sectional study in Chinese PLWH
14
 reported the coverage of annual VL testing among PLWH 
retained in care had increased from 50% in 2009 to 84% in 2015. According to WHO guidelines 
and current Chinese standard practices, the first VL test is usually performed between 6 months 
and 12 months after ART initiation
3,15
. Missing VL monitoring within the first year of ART is 
associated with worse retention in care, faster disease progression and increased mortality
16–18
. 
However, a cohort study
18
 in rural China reported only 68% of PLWH had VL tests in their first-
year on ART.  
 
Reasons for lack of or delayed VL testing can be multifaceted.  Structural factors may include 
insufficient laboratory network system, centralized VL testing strategy, shortage of professionals 
and limited staff training
4,19,20
. Patient individual-level characteristics have influences on the 
utilization of healthcare service, which further affect the coverage and timeliness of VL testing. 
HIV transmission route, CD4 cell count, WHO stage, ART regimen and awareness of VL 
benefits are all reported as individual-level factors
4,21–23
.    
30 
 
Yunnan has been one of the provinces with the most serious HIV/AIDS epidemic and which 
pioneered ART implementation
10,24
. The cumulative number of PLWH in Yunnan accounted for 
21% of the total number in China
25
. The main HIV transmission route has changed from 
injection drug use (IDU) to heterosexual contact
25,26
, which accounted for over 80% of newly 
diagnosed cases
24
. By the end of 2016, twenty-two laboratories in Yunnan were capable of VL 
testing, however, only one was located in and provided service for Wenshan Prefecture
27
. 
Wenshan is located in a mountainous region, where traffic and economy have not been fully 
developed
28–31
. About 61% of the population is living in rural areas
28,29. Han ethnicity, China’s 
main ethnicity, only accounted for 42.0% of the Wenshan population; Zhuang, Miao, Yi, and 
other ethnic minorities accounted for 58.0%
29
. Wenshan is one of the regions with the largest 
number of PLWH within the province. Nine county-level and one prefecture-level facilities 
provide ART and laboratory tests to all PLWH in the prefecture. To our knowledge, there have 
been few studies focusing on the access to VL testing in China’s rural areas. To assess the 
coverage and timeliness of VL test and identified specific factors associated with lack of or 
delayed VL testing, we did a clinic-based retrospective cohort study in Wenshan. Data used in 
our study were extracted from medical records and a survey conducted among PLWH. 
 
Methods 
Study sites 
Three of the ten ART clinics in Wenshan Prefecture were selected as our study sites (Site A, B, 
and C). Site A was attached to a county-level hospital and had the largest number of PLWH 
receiving ART in Wenshan. Site B was attached to a prefecture-level hospital, where the only 
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VL testing laboratory was located. Site C was a county-level independent specialized HIV/AIDS 
care center with the third largest number of PLWH. 
 
Study design 
A clinic-based retrospective study was conducted among a cohort of PLWH who initiated ART 
between Jan 1, 2015 and Dec 31, 2016 in ART sites A, B and C. Each participant was followed 
up from ART initiation to the date of the first valid VL test, death, loss to follow-up (LTFU), 
transferring to other ART facilities or Dec 31, 2018, whichever came first. To supplement more 
necessary information, a survey was conducted among a subset of participants from Jan to Mar 
2019. Cox proportional hazard models were used to identify factors associated with the VL 
testing timing.  
 
Enrollment 
There were two study cohorts. Cohort 1, or the source cohort, included PLWH who (a) initiated 
ART from Jan 1, 2015 to Dec 31, 2016, (b) initiated ART in Site A, B and C, (c) were aged≥18 
years when initiated ART, (d) retained in care for more than 6 months (Figure 2.1). Cohort 2, or 
the survey cohort, was a subset of the source cohort. A survey was conducted from Jan to Mar 
2019 in our three study sites. Criteria for the survey cohort included (a) belonging to the source 
cohort, (b) visiting the study ART sites during the three-month survey period. When patients 
visited the study sites during the survey period, the local healthcare providers first preliminarily 
checked their medical records for eligibility of the source cohort. For eligible patients, the staff 
then simply introduced the study and invited them to participate in the survey. Since PLWH was 
a sensitive population, the healthcare providers were in charge of making the initial screen and 
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contact with patients on behalf of the investigator. If the potential participants agreed to 
participate, they would be referred to the investigator. The investigator then double-checked the 
eligibility and conducted a questionnaire survey to the eligible ones. Oral informed consent was 
obtained before the survey (Figure 2.1).  
 
Data collection 
There were two data sources: medical records in ART sites and the survey. From medical 
records, three types of data were extracted, including important dates (e.g. dates of ART 
initiation and VL tests), basic socio-demographic information (e.g. gender, age, marital status, 
ethnicity, and education level), and clinical characteristics (e.g. HIV infection route, baseline 
CD4 cell count, and WHO clinical stage). All VL testing dates from ART initiation to Dec 31, 
2018 were extracted. Data were extracted at the end of 2019 March by healthcare providers who 
worked in the ART sites and had access to medical records.  
 
The survey was conducted from Jan to Mar 2019 in ART Sites A, B and C using a structured 
questionnaire. After being recruited in the survey, participants filled out the questionnaire under 
the investigator’s guidance on the same day they visited the ART sites. If the participant was not 
able to read, the investigator would do a face-to-face survey and fill out the questionnaire 
according to the participant’s answer. Characteristics during the first year of ART were collected 
for this study, mainly including socio-demographic information (e.g. occupation, location of 
home and distance from home to ART site). The patient ID was collected to link survey data to 
medical records, and it was deleted once data were linked. It took 5-10 minutes to complete a 
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questionnaire. After the survey, each participant received a gift equivalent to 20 Yuan (about 3 
USD). 
 
Measurements of VL testing timeliness 
According to current standard practice in China, VL testing is not provided before or at the very 
beginning of ART. Viral load tests within 3 months after ART initiation were excluded since the 
duration of ART might not be enough to evaluate treatment response. VL tests after 3 months of 
ART were regarded as valid VL tests. Two measurements were used to assess the timeliness of 
VL testing. The first measurement was the cumulative rate (%) of valid VL testing at 12 months 
after ART initiation. The second measurement was VL testing event, which was defined as the 
first valid VL test after ART initiation. Patients were censored at death, LTFU, transferring to 
other ART facilities or on Dec 31, 2018. The time of VL testing in our study referred to the date 
of blood sample collection. 
 
Data analysis 
Descriptive analyses were conducted to describe the characteristics of both the source cohort and 
the survey cohort. Categorical variables were compared by Chi-square tests, and continuous 
variables were compared by Wilcoxon test. The cumulative rates (%) of having VL test at 12, 18 
and 24 months after ART initiation were calculated in both cohorts. VL testing rate (%) at 12 
months would be presented by three ART sites. Time to VL testing event was calculated as the 
difference between the date of ART initiation and the date of first valid VL testing or censored 
date (person-year [PY]). Cox proportional hazard models were used to identify factors associated 
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with VL testing timing. Hazard ratio (HR), 95% confidence interval (CI) and p-value were 
presented. Data were analyzed using SAS 9.4 software (SAS Institute, Cary, NC, US) 
 
Ethics 
The study was reviewed and approved by the Institutional Review Board (IRB) of University of 
California, Los Angeles (UCLA) in the U.S. and by National Center for AIDS/STD Control and 
Prevention (NCAIDS), Chinese Center for Disease Center and Prevention (China CDC).  
 
Results 
Figure 2.1 shows the source cohort development and the sampling strategy for the survey cohort. 
A total of 911 PLWH initiated ART from Jan 1, 2015 to Dec 31, 2016 in the three selected ART 
sites, and 815 adult PLWH (89.5%) were retained in care for at least 6 months, with 425 in Site 
A, 124 in Site B and 266 in Site C. Patients who visited the three ART sites during 2019 Jan to 
Mar and belonged to the source cohort were eligible to be invited to participate in the survey. 
The numbers of patients who were screened and invited were not recorded by the healthcare 
providers. There were 293 PLWH accepted the invitation and were referred to the investigator. 
After double-checking for eligibility, 264 (90.1%) of those patients were included in the survey 
cohort, with 85 from Site A, 84 from Site B and 95 from Site C. The proportions of PLWH who 
participated in the survey were 20% at Site A, 67.7% at Site B and 35.7% at Site C, which were 
significantly different across three study sites (p<0.001). Sampling weights were added in the 
Cox model to correct the unbalance.  
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Characteristics of the source cohort and the survey cohort were shown in Table 2.1. In the source 
cohort, the median age was 42 years (IQR: 32-51), and 60.3% were male. About 94.5% PLWH 
reported they were infected HIV through heterosexual contacts. About 48% of participants were 
illiterate or at elementary school level education. The median CD4 cell count at ART initiation 
was 316/μL (IQR: 199-447). The basic demographic and clinical characteristics of PLWH 
participated in or not participated in the survey were comparable, except that more PLWH in the 
survey cohort were at WHO stage I & II than the population who didn’t participate in the survey 
(80% vs. 72%, p=0.019).  
Figure 2.1 Flowchart: the development of source cohort and survey cohort 
ART=antiretroviral therapy. PLWH: people living with HIV. Dropout was defined as loss to follow-
up or discontinuation ART. The survey cohort (n=264) was a subset of the source cohort (N=815).  
*: The numbers of patients who were preliminary screened by the healthcare providers and invited 
to participate in the survey was not recorded.  
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Table 2.1 Basic demographic and clinical characteristics of source cohort (N=815), survey cohort 
(n= 264) and PLWH who didn’t participate in the survey (n=551) 
Characteristics 
Total cohort 
(n%) 
PLWH 
participated 
survey (n%) 
PLWH not 
participated 
survey (n%) 
P-value* 
Overall 815 (100.0) 264 (100.0) 551 (100.0) 
 
ART site 
    
  Site A 425 (52.2) 85 (32.2) 340 (61.7) <0.001 
  Site B 124 (15.2) 84 (31.8) 40 (7.3) 
 
  Site C 266 (33.6) 95 (36.0) 171 (31.0) 
 
Gender 
    
  Male 491 (60.3) 153 (58.0) 338 (61.3) 0.355 
  Female 324 (39.7) 111 (42.0) 213 (38.7) 
 
Age at ART initiation, years 
    
  Median (IQR) 42 (32, 51) 42 (32, 51) 42 (32, 52) 0.574 
  18-30 167 (20.5) 52 (19.7) 115 (20.9) 0.501 
  30-45 321 (39.4) 110 (41.7) 211 (38.3) 
 
  45-60 215 (26.4) 72 (27.3) 143 (26.0) 
 
  >60 112 (13.7) 30 (11.4) 82 (14.9) 
 
Marital status  
    
  Single  230 (28.2) 81 (30.7) 149 (27.0) 0.280 
  Not single 585 (71.8) 183 (69.3) 402 (73.0) 
 
Ethnicity 
    
  Han 478 (58.7) 151 (57.2) 327 (59.4) 0.560 
  Minority 337 (41.3) 113 (42.8) 224 (40.6) 
 
Education level 
    
  Illiteracy & elementary 
school 
389 (48.0) 124 (47.2) 265 (48.4) 0.171 
  Middle school 295 (36.4) 89 (33.8) 206 (37.6) 
 
  High school & above 127 (15.6) 50 (19.0) 77 (14.0) 
 
Occupation** 
    
  Farmer -- 54 (20.5) -- -- 
  Permanent job -- 40 (15.2) -- 
 
  Temporary job -- 131 (49.6) -- 
 
  No job, housework or others -- 39 (14.7) -- 
 
Living in the same county 
with their ART site**     
  Yes -- 195 (75.3) -- -- 
  No -- 64 (24.7) -- 
 
Distance between home and 
ART site**     
  <2-hour drive -- 156 (59.1) -- -- 
  >2-hour drive -- 108 (40.9) -- 
 
Time of ART initiation 
    
  2015 362 (44.4) 128 (48.5) 234 (42.5) 0.106 
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  2016 453 (55.6) 136 (51.5) 317 (57.5) 
 
Route of HIV transmission 
    
  Heterosexual behaviors 770 (94.5) 252 (95.5) 518 (94.0) 0.398 
  Other 45 (5.5) 12 (4.5) 33 (6.0) 
 
CD4 cell count/μL when 
ART initiated     
  Median (IQR) 316 (199, 447) 321 (210, 452) 314 (193, 443) 0.620 
  <200 238 (29.2) 72 (27.3) 166 (30.1) 0.532 
  200-350 242 (29.7) 82 (31.1) 160 (29.0) 
 
  350-500 207 (25.4) 63 (23.9) 144 (26.1) 
 
  >500 128 (15.7) 47 (17.8) 83 (14.7) 
 
WHO clinical stage when 
ART initiated     
  Stage I & II 606 (74.4) 210 (79.6) 396 (71.9) 0.019 
  Stage III & IV 209 (25.6) 54 (20.4) 155 (28.1)   
*: Chi-square test for categorical variables; Wilcoxon rank-sum test for continuous variables 
**: Only PLWH who participated the survey provided these information 
PLWH: people living with HIV, ART: antiretroviral therapy 
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Cumulative VL testing rate (%) 
Among 815 PLWH in the source cohort, 1 (0.1%) person died, 5 (0.6%) transferred to other 
ART facilities, 20 (2.5%) were lost to follow-up, and 2 (0.2%) didn’t have VL test throughout 
the observed period. Finally, 787 (96.6%) took at least one valid VL test during our observed 
period, and 58.5%, 78.1%, 93.0% had VL test by 12, 18, and 24 months of ART, respectively. 
The median time from ART initiation to the first valid VL test was 10.7 months (IQR: 7.8-16.5). 
The cumulative VL testing rates in the source population are shown by ART sites in Figure 2.2a. 
The cumulative rate (%) of VL test at 12 months was highest for Site C (73.3%), followed by site 
B (61.3%), and lowest for Site A (48.5%), p<0.001. At 24 months of ART, the overall VL 
testing coverage was 93.0%, with no significant difference among the three ART sites (p=0.480). 
 
 
 
Figure 2.2b Cumulative rates of VL testing at 
12, 18 and 24 months after ART initiation: 
survey cohort (n=264) 
Figure 2.2a Cumulative rates of VL testing at 
12, 18 and 24 months after ART initiation: 
source cohort (N=815)  
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Among 264 people in the survey cohort, only 1 (0.4%) was LTFU and 263 (99.6%) had VL tests 
during the observed period, among whom 63.6%, 81.1%, 97% took VL test by 12, 18, and 24 
months of ART, respectively. The median timing of the first VL test was 10.1 months (IQR: 7.3, 
15.6). Similar to the source cohort, the cumulative VL testing rates (%) by 12 months in ART 
Site C was significantly higher than the rates in Site A and B. (Figure 2.2b).  
 
Stratified analysis by three ART sites 
Table 2.2a showed participants’ characteristics and VL testing rates (%) at 12 months by study 
sites in source cohort (N=815). Participants in Site C tended to be younger (p=0.009), be ethnic 
minorities (p<0.001), have a lower education level (p<0.001) and higher CD4 cell count at ART 
initiation (p<0.001). The cumulative VL testing rates (%) at 12 months in Site A, B and C were 
different by age group (18-30 group: p<0.001; 30-45 group: p=0.001; 45-60 group: p=0.002; 
>60 group: p=0.557), marital status (Single group: p=0.212; married group: p<0.001), education 
level (Illiteracy & elementary school group: p=0.008; Middle school group: p<0.001; High 
school & above group: p=0.076), baseline CD4 cell count (<200/μL group: p=0.374; 200-350/μL 
group: p<0.001; 350-500/μL group: p=0.001; >500/μL group: p=0.015) and baseline WHO 
clinical stages (Stage I & II group: p<0.001; Stage III & IV group: p=0.248).  
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Table 2.2a. Participant characteristics by ART site and rates of taking VL test within 12 months after ART initiation: source cohort 
(N=815)  
Characteristics  
Participant characteristics by ART sites, (n%) 
 
VL testing rates at 12 months after ART 
initiation, % 
  Site A Site B Site C P-value   Overall Site A Site B Site C P-value 
Overall 
 
425 (100.0) 124 (100.0) 266 (100.0) 
  
58.5 48.5 61.3 73.3 <0.001 
Gender 
             Male 
 
255 (60.0) 69 (55.7) 167 (62.8) 0.402 
 
59.9 52.6 59.4 71.3 <0.001 
  Female 
 
170 (40.0) 55 (44.4) 99 (37.2) 
  
56.5 42.4 63.6 76.8 <0.001 
Age at ART 
initiation, 
years 
             Median (IQR) 
 
43 (33, 54) 42 (32, 50) 39 (30, 49) 0.009 
        18-30 
 
78 (18.4) 22 (17.7) 67 (25.2) 0.030 
 
61.1 42.3 63.6 82.1 <0.001 
  30-45 
 
155 (36.5) 55 (44.4) 111 (41.7) 
  
54.8 44.5 60.0 66.7 0.001 
  45-60 
 
121 (28.5) 32 (25.8) 62 (23.3) 
  
60.9 51.2 65.6 77.4 0.002 
  >60 
 
71 (16.7) 15 (12.1) 26 (9.8) 
  
60.7 59.2 53.3 69.2 0.557 
Marital status  
             Single  
 
125 (29.4) 42 (33.9) 63 (23.7) 0.084 
 
57.4 54.4 52.4 66.7 0.212 
  Not single 
 
300 (70.6) 82 (66.1) 203 (76.3) 
  
59.0 46.0 65.9 75.4 <0.001 
Ethnicity 
             Han 
 
271 (63.8) 93 (75.0) 114 (42.9) <0.001 
 
55.2** 47.2 58.1 71.9 <0.001 
  Minority 
 
154 (36.2) 31 (25.0) 152 (57.1) 
  
63.2** 50.7 71.0 74.3 <0.001 
Education 
level 
             Illiteracy & 
elementary 
school 
 
211 (49.7) 33 (27.1) 145 (54.9) <0.001 
 
59.1 52.6 57.6 69.0 0.008 
  Middle school 
 
158 (37.2) 47 (38.5) 90 (34.1) 
  
58.0 43.7 61.7 81.1 <0.001 
  High school & 
above 
 
56 (13.2) 42 (34.4) 29 (11.0) 
  
57.5 46.4 64.3 69.0 0.076 
Time of ART 
initiation 
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  2015 
 
 183 (43.1) 55 (44.4) 124 (46.6) 0.657 
 
52.8*** 36.6 50.9 77.4 <0.001 
  2016 
 
242 (56.9) 69 (56.6) 142 (53.4) 
  
63.1*** 57.4 69.6 69.7 0.027 
CD4 cell 
count/μL when 
ART initiated 
             Median (IQR) 
 
304 (191, 431) 296 (164, 391) 368 (231, 514) <0.001 
        <200 
 
111 (26.1) 39 (31.5) 88 (33.1) 0.004 
 
61.3 58.6 56.4 67.1 0.374 
  200-350 
 
141 (33.2) 38 (30.7) 63 (23.7) 
  
55.4 42.6 55.3 84.1 <0.001 
  350-500 
 
115 (27.1) 34 (27.4) 58 (21.8) 
  
58.0 47.0 67.7 74.1 0.001 
  >500 
 
58 (13.7) 13 (10.4) 57(21.4) 
  
60.2 46.6 76.9 70.2 0.015 
WHO clinical 
stage when 
ART initiated 
             Stage I & II 
 
299 (70.4) 103 (83.1) 204 (76.7) 0.010 
 
60.9*** 50.2 63.1 78.4 <0.001 
  Stage III & IV 
 
126 (29.6) 21 (16.9) 62 (23.3) 
  
48.8*** 44.4 52.4 56.5 0.248 
VL: viral load; PLWH: people living with HIV, ART: antiretroviral therapy 
*：the VL testing rate at 12 months after ART initiation were significantly different within categories of this characteristic, p<0.1;  
**：the VL testing rate at 12 months after ART initiation were significantly different within categories of this characteristic, p<0.05; 
***：the VL testing rate at 12 months after ART initiation were significantly different within categories of this characteristic, p<0.01; 
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Among the survey cohort (n=264, Table 2.2b), in addition to characteristics mentioned in the 
source cohort, participants in Site C were also more likely to be married (p=0.019), have less 
permanent jobs (p<0.001) and have shorter travel distance between home and ART site 
(p=0.003). Additional characteristics which could differentiate VL testing rates (%) in three ART 
sites included occupation (Farmer group: p=0.142; Permanent job group: p=0.446; Temporary 
job group: p<0.001; Other group: p=0.035) and location of home (In the same county of ART site 
group: p<0.001; Not in the same county of ART site group: p=0.559).
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Table 2.2b Participant characteristics by ART site and VL testing rates (%) at 12 months after ART initiation: survey cohort (N=264) 
Characteristics  
Participant characteristics by ART sites, (n%) 
 
VL testing rates at 12 months after ART 
initiation, % 
  Site A Site B Site C P-value   Overall Site A Site B Site C P-value 
Overall 
 
85 (100.0) 84 (100.0) 95 (100.0) 
  
63.6 49.4 56.0 83.2 <0.001 
Gender 
             Male 
 
51 (60.0) 47 (56.0) 55 (57.9) 0.868 
 
63.4 52.9 59.6 76.4 0.035 
  Female 
 
34 (40.0) 37 (44.0) 40 (42.1) 
  
64.0 44.1 51.4 92.5 <0.001 
Age at ART 
initiation, years 
             Median (IQR) 
 
41 (32, 50) 41 (31, 49) 43 (33, 51) 0.662 
        18-30 
 
16 (18.8) 18 (21.4) 18 (18.9) 0.664 
 
65.4 43.8 61.1 88.9 0.020 
  30-45 
 
36 (42.4) 37 (44.1) 37 (39.0) 
  
64.6 52.8 51.4 89.2 <0.001 
  45-60 
 
21 (24.7) 19 (22.6) 32 (33.7) 
  
65.3 47.6 63.2 78.1 0.072 
  >60 
 
12 (14.2) 10 (11.9) 8 (8.4) 
  
55.5 50.0 50.0 62.5 0.832 
Marital status  
             Single  
 
27 (31.8) 34 (40.5) 20 (21.1) 0.019 
 
66.7 63.0 44.1 70.0 0.131 
  Not single 
 
58 (68.2) 50 (59.5) 75 (78.9) 
  
56.8 43.1 64.0 86.7 <0.001 
Ethnicity 
             Han 
 
51 (60.0) 63 (75.0) 37 (39.0) <0.001 
 
57.0*** 45.1 52.4 81.0 0.002 
  Minority 
 
34 (40.0) 21 (25.0) 58 (61.0) 
  
72.6*** 55.9 66.7 84.5 0.010 
Education level 
             Illiteracy & 
elementary school 
 
43 (50.6) 24 (28.6) 57 (60.6) <0.001 
 
67.7 53.5 58.3 82.5 0.005 
  Middle school 
 
31 (36.5) 29 (34.5) 29 (30.9) 
  
57.3 45.2 44.8 82.8 0.003 
  High school & 
above 
 
11 (12.9) 31 (36.9) 8 (8.5) 
  
64.0 45.5 64.5 87.5 0.168 
Occupation 
             Farmer 
 
28 (32.9) 13 (15.5) 13 (13.7) <0.001 
 
64.8 53.6 69.2 84.6 0.142 
  Permanent job 
 
10 (11.8) 22 (26.2) 8 (8.4) 
  
55.0 50.0 50.0 75.0 0.446 
  Temporary job 
 
37 (43.5) 43 (51.2) 51 (53.7) 
  
66.4 48.7 58.1 86.3 <0.001 
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  No job or others 
 
10 (11.8) 6 (7.1) 23 (24.2) 
  
61.5 40.0 33.3 78.3 0.035 
Living in the same 
county with their 
ART site 
             Yes 
 
63 (75.9) 59 (71.1) 73 (78.5) 0.517 
 
64.1 47.6 54.2 86.3 <0.001 
  No 
 
20 (24.1) 24 (28.9) 20 (21.5) 
  
65.6 60.0 62.5 75.0 0.559 
Distance between 
home and ART 
site 
             <2-hour drive 
 
56 (65.9) 37 (44.1) 63 (66.3) 0.003 
 
68.0* 51.8 59.5 87.3 <0.001 
  >2-hour drive 
 
29 (34.1) 47 (55.9) 32 (33.7) 
  
57.0* 44.8 53.2 75.0 0.044 
Time of ART 
initiation 
             2015 
 
45 (52.9) 39 (46.4) 44 (46.3) 0.608 
 
55.5*** 37.8 46.2 81.8 <0.001 
  2016 
 
40 (47.1) 45 (53.6) 51 (53.7) 
  
71.3*** 62.5 64.4 84.3 0.034 
CD4 cell count/μL 
when ART 
initiated 
             Median (IQR) 
 
346 (225, 455) 294 (156, 390) 329 (221, 485) 0.060 
        <200 
 
14 (16.5) 25 (29.8) 3 (34.7) 0.049 
 
77.2 64.3 64.0 81.8 0.247 
  200-350 
 
30 (35.3) 27 (32.1) 25 (26.3) 
  
58.5 46.7 40.7 92.0 <0.001 
  350-500 
 
23 (27.1) 23 (27.4) 17 (17.9) 
  
60.3 52.2 60.8 76.5 0.187 
  >500 
 
18 (21.2) 9 (10.7) 20 (21.1) 
  
63.8 55.6 66.7 80.0 0.073 
WHO clinical 
stage when ART 
initiated 
             Stage I & II 
 
62 (72.9) 72 (85.7) 76 (80.0) 0.119 
 
66.2* 51.6 57.0 86.8 <0.001 
  Stage III & IV 
 
23 (27.1) 12 (14.3) 19 (20.0) 
  
53.7* 43.5 50.0 68.4 0.261 
VL: viral load; PLWH: people living with HIV, ART: antiretroviral therapy 
*：the VL testing rate at 12 months after ART initiation were significantly different within categories of this characteristic, p<0.1;  
**：the VL testing rate at 12 months after ART initiation were significantly different within categories of this characteristic, p<0.05; 
***：the VL testing rate at 12 months after ART initiation were significantly different within categories of this characteristic, p<0.01; 
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Determinants of VL testing timeliness   
As shown in Table 2.3a, 815 PLWH in the source cohort contributed 851.1 PY of observed time, 
during which 787 PLWH took at least one VL test. The overall incidence rate of VL testing was 
0.92 per PY. PLWH who were older than 45 years (45-60 group: adjusted HR [aHR]=1.23, 95% 
CI=1.03-1.48; >60 group: aHR=1.34, 95% CI=1.07-1.70), were an ethnic minority (aHR=1.24, 
95% CI=1.07-1.45), initiated ART in 2016 (aHR=1.32, 95% CI=1.14-1.53), were at WHO stage 
I & II (aHR=1.40, 95% CI=1.18-1.65) and received ART in Site C (aHR=2.21, 95% CI=1.89-
2.26) were more likely to take VL tests earlier. CD4 cell count was removed from the 
multivariate model since a correlation between CD4 cell count and WHO stage was identified 
(r=-0.404, p<0.001) and CD4 cell count was not significant in univariate analysis.  
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Table 2.3a Factors associated with VL testing timing by Cox proportional modeling: source cohort, N=815 
Variables 
Participants 
who had 
VL test 
Observed 
time, PY 
Rate of 
VL test, 
per PY 
Crude HR (95% CI) p-value Adjusted HR (95%CI) p-value 
Overall 787 851.1 0.92 
    
Gender 
       
  Male 477 510.9 0.93 1.00 
 
1.00 
 
  Female 310 340.2 0.91 0.98 (0.85, 1.13) 0.743 1.02 (0.88, 1.18) 0.788 
Age at ART initiation, 
years        
  18-30 161 172.9 0.93 1.07 (0.88, 1.30) 0.487 1.05 (0.86, 1.28) 0.646 
  30-45 307 345.3 0.89 1.00 
 
1.00 
 
  45-60 209 220.1 0.95 1.12 (0.94, 1.33) 0.212 1.23 (1.03, 1.48) 0.025 
  >60 110 112.8 0.98 1.19 (0.96, 1.48) 0.120 1.34 (1.07, 1.70) 0.012 
Marital status  
       
  Single  225 243.4 0.92 1.00 (0.86, 1.17) 0.982 1.03 (0.88, 1.22) 0.698 
  Not single 562 607.7 0.92 1.00 
 
1.00 
 
Ethnicity 
       
  Han 458 522.2 0.88 1.00 
 
1.00 
 
  Minority 329 328.8 1.00 1.27 (1.10, 1.46) 0.001 1.24 (1.07, 1.45) 0.005 
Education level 
       
  Illiteracy & elementary 
school 
373 398.9 0.94 1.00 
 
1.00 
 
  Middle school 287 310.1 0.93 0.94 (0.81, 1.10) 0.428 1.11 (0.94, 1.32) 0.218 
  High school & above 123 138.6 0.89 0.88 (0.72, 1.08) 0.222 1.02 (0.81, 1.27) 0.896 
ART site 
       
  Site A 416 511.5 0.81 1.00 
 
1.00 
 
  Site B 121 131.7 0.92 1.24 (1.01, 1.53) 0.035 1.24 (1.00, 1.53) 0.050 
  Site C 250 207.8 1.20 2.21 (1.89, 2.60)  <0.001 2.20 (1.87, 2.60) <0.001 
Time of ART initiation 
       
  2015 353 415.8 0.85 1.00 
 
1.00 
 
  2016 434 435.3 1.00 1.42 (1.23, 1.63) <0.001 1.32 (1.14, 1.53) <0.001 
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CD4 cell count/μL when 
ART initiated 
 
      
  <200 225 241.0 0.93 1.00 
   
  200-350 234 260.7 0.90 0.91 (0.76, 1.09) 0.310 
  
  350-500 204 218.4 0.93 0.98 (0.81, 1.18) 0.827 
  
  >500 124 131.1 0.95 1.00 (0.80, 1.24) 0.963 
  
WHO clinical stage 
when ART initiated        
  Stage I & II 590 611.4 0.96 1.31 (1.12, 1.54) 0.001 1.40 (1.18, 1.65) <0.001 
  Stage III & IV 197 239.7 0.82 1.00 
 
1.00 
 
VL: viral load; PLWH: people living with HIV, ART: antiretroviral therapy; PY: person-year 
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Among participants in the survey cohort (n=264), the total observed time was 259.1 PY, and 263 
had VL testing (Table 2.3b). Similar to the results in the source cohort, PLWH who initiated 
ART in 2016 (aHR=1.45, 95% CI=1.12-1.89), in ART site C (aHR=3.22, 95% CI=2.28-4.55) 
and were at WHO stage I & II (aHR=1.44, 95% CI=1.03-2.01) were more likely to undergo VL 
test earlier. Additionally, participants who lived farther than 2-hour drive from ART site 
(aHR=0.72, 95% CI=0.54-0.95) and had a permanent job (aHR=0.67, 95% CI=0.45-1.00) were 
more likely to delay VL testing. After adding sampling weights in the multivariate model, age 
(18-30 years vs. 30-45 years: aHR=0.78, 95% CI=0.63-0.96), ethnicity group (ethnic minority 
vs. Han: aHR=1.39, 95% CI=1.19-1.62) and education level (high school and above vs. illiteracy 
& elementary school: aHR=1.29, 95% CI=1.00-1.66) also showed weak effects on VL testing 
timing. Besides the correlation between CD4 cell count and WHO stage (r=-0.406, r<0.001), a 
correlation was also identified within another pair of variables: living in the same county with 
their ART site and travel distance (r=0.608; p<0.001). Only travel distance was included in the 
multivariate models. 
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Table 2.3b. Factors associated with VL testing timing by Cox proportional modeling: survey cohort, N=264 
Variables 
Participants 
who had 
VL test 
Observed 
time, PY 
Rate of 
VL test, 
per PY 
Crude HR 
(95% CI) 
p-
value 
Adjusted HR 
(95%CI) 
p-
value 
Weighted* 
adjusted HR 
(95%CI) 
p-
value 
Overall 263 259.1 1.02 
      
Gender 
         
  Male 153 150.1 1.02 1.00 
 
1.00 
 
1.00 
 
  Female 110 108.9 1.01 0.97 (0.76, 1.25) 0.825 1.10 (0.84, 1.45) 0.488 1.14 (0.98, 1.34) 0.100 
Age at ART 
initiation, years          
  18-30 52 51.8 1.00 0.99 (0.71, 1.38) 0.948 0.95 (0.66, 1.36) 0.952 0.78 (0.63, 0.96) 0.019 
  30-45 110 107.4 1.02 1.00 
 
1.00 
 
1.00 
 
  45-60 71 68.7 1.03 1.05 (0.78, 1.42) 0.741 0.85 (0.60, 1.21) 0.379 0.85 (0.69, 1.04) 0.117 
  >60 30 31.2 0.96 0.97 (0.64, 1.15) 0.864 0.99 (0.60, 1.64) 0.963 0.92 (0.69, 1.24) 0.589 
Marital status  
         
  Single  81 85.1 0.95 0.87 (0.67, 1.13) 0.281 0.96 (0.71, 1.30) 0.795 1.18 (0.99, 1.41) 0.063 
  Not single 182 174.0 1.05 1.00 
 
1.00 
 
1.00 
 
Ethnicity 
         
  Han 150 161.3 0.93 1.00 
 
1.00 
 
1.00 
 
  Minority 113 97.8 1.16 1.51 (1.18, 1.93) 0.001 1.29 (0.98, 1.68) 0.071 1.39 (1.19, 1.62) <0.001 
Education level 
         
  Illiteracy & 
elementary 
school 
124 115.9 1.07 1.00 
 
1.00 
 
1.00 
 
  Middle school 88 92.4 0.95 0.78 (0.56, 1.02) 0.072 0.99 (0.72, 1.37) 0.944 0.93 (0.77, 1.12) 0.437 
  High school & 
above 
50 50.5 0.99 0.88 (0.63, 1.22) 0.439 1.41 (0.95, 2.13) 0.087 1.29 (1.00, 1.66) 0.043 
ART site 
         
  Site A 84 100.1 0.84 1.00 
 
1.00 
 
1.00 
 
  Site B 84 94.7 0.89 1.07 (0.79, 1.46) 0.649 1.09 (0.84, 1.45) 0.625 1.02 (0.82, 1.28) 0.833 
  Site C 95 64.2 1.48 3.07 (2.27, 4.15) <0.001 3.22 (2.28, 4.55) <0.001 3.24 (2.70, 3.90) <0.001 
Occupation 
         
  Farmer 54 55.3 0.98 0.85 (0.62, 1.17) 0.316 1.02 (0.72, 1.45) 0.923 1.02 (0.84, 1.24) 0.851 
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  Permanent job 40 44.7 0.89 0.71 (0.50, 1.02) 0.064 0.67 (0.45, 1.00) 0.049 0.71 (0.56, 0.90) 0.005 
  Temporary job 130 122.9 1.06 1.00 
 
1.00 
 
1.00 
 
  Other 39 36.2 1.08 1.01 (0.71, 1.45) 0.956 0.82 (0.52, 1.29) 0.397 0.86 (0.66, 1.11) 0.253 
Living in the 
same county 
with their ART 
site 
         
  Yes 195 187.8 1.04 1.00 
     
  No 63 63.9 0.99 0.92 (0.69, 1.22) 0.564 
    
Distance 
between home 
and ART site 
         
  <2-hour drive 156 143.8 1.08 1.00 
 
1.00 
 
1.00 
 
  >2-hour drive 107 115.3 0.93 0.73 (0.57, 0.94) 0.016 0.72 (0.54, 0.95) 0.019 0.70 (0.59, 0.83) <0.001 
Time of ART 
initiation          
  2015 127 140.0 0.91 1.00 
 
1.00 
 
1.00 
 
  2016 136 119.0 1.14 1.50 (1.17, 1.92) 0.001 1.45 (1.12, 1.89) 0.005 1.54 (1.32, 1.79) <0.001 
CD4 cell 
count/μL when 
ART initiated 
         
  <200 72 63.2 1.14 1.00 
     
  200-350 82 82.3 1.00 0.81 (0.59, 1.12) 0.206 
    
  350-500 62 67.6 0.92 0.70 (0.50, 0.98) 0.039 
    
  >500 47 46.0 1.02 0.86 (0.59, 1.25) 0.862 
    
WHO clinical 
stage when ART 
initiated 
         
  Stage I & II 209 201.1 1.04 1.27 (0.94, 1.72) 0.12 1.44 (1.03, 2.01) 0.03 1.56 (1.30, 1.89) <0.001 
  Stage III & IV 54 58.0 0.93 1.00 
 
1.00 
 
1.00 
 VL: viral load; PLWH: people living with HIV, ART: antiretroviral therapy; PY: person-year 
* Sampling weights were added in multivariate Cox model 
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Discussion 
The coverage and timeliness of viral load testing was an important but easily-neglected link in 
the HIV/AIDS care continuum, especially in resource-limited settings. In our study, 90% of 
PLWH were retained in care longer than 6 months, among whom 58.5% underwent their first VL 
test within 12 months after ART initiation, which was in agreement with other studies conducted 
in rural southeast China
18,32
. Patients initiating ART in 2016 tended to have timelier VL testing 
than those initiating in 2015 (p<0.001). However, universal access to timely VL testing remained 
a challenge in the real-world settings.  
 
VL tests were performed significantly earlier in ART Site C than Site A & B. Figure 2.2a and 
2.2b showed age, marital status, education level, baseline CD4 cell count and WHO stage might 
modify the association between ART sites and VL testing timing. However, after controlling 
available variables, Site C was still an independent better predictor for timely VL testing. Hence, 
the early VL testing in Site C could not be explained by those patient individual-level 
characteristics. Site C was an independent specialized HIV/AIDS care center with a higher 
doctor-patient ratio than Site A & B (Site A vs. B vs. C=1/600 vs. 1/600 vs.1/300). Additionally, 
a policy of government purchasing public service was well implemented in Site C. The local 
government purchased HIV care services from non-governmental organizations (NGOs) as an 
auxiliary method to improve ART
33
. In Site C, NGO staff organized patient education meetings 
twice a month and provided peer support to patients, which could be helpful to improve patients’ 
adherence and ART outcomes
34,35
.  
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In our study, PLWH at WHO stage I & II at ART initiation were more likely to undergo VL test 
timely. Patients could only undergo VL tests when they visited the ART sites, hence the 
frequency of follow-up visits and healthcare service utilization might directly influence the VL 
monitoring. Studies
36,37
 in resource-limited settings reported advanced WHO stage (Stage III & 
Stage IV ) at ART initiation were associated with fewer follow-up visits. However, a study in 
Canada indicated HIV disease increased the possibility to visit health care settings
21
. The 
discrepancy could be due to the different levels of health care system development in resource-
limited settings and well-resourced settings. In rural China, further improvement of HIV care 
service accessibility is needed. 
 
Cox models in the survey cohort showed that distance between home and ART sites significantly 
adversely affected VL testing timeliness. Although ART coverage in China had been greatly 
scaled up, ART in rural areas was still mainly centralized in county- and prefecture/city-level 
facilities. Quite a few PLWH in Wenshan living in mountainous areas without developed traffic, 
and it took them hours to arrive at the ART site secured. Studies
38–40
 reported longer travel 
distance and time made HIV care less accessible, which resulted in less health service utilization, 
suboptimal ART outcomes and increased LTFU. The results of our study provided more 
evidence of the necessity to decentralization ART service to township- or community-level 
facilities in remote rural regions. Higher level HIV care facilities should cooperate with township 
hospitals or provide outreach services so that VL testing blood samples could be collected more 
conveniently
38
.    
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An interesting finding was that ethnic minority PLWH were more likely to undergo VL testing 
earlier than Han ethnicity. Studies
41–43
 reported that the HIV epidemic was more serious among 
ethnic minority populations in this area. However, the proportion of ethnic minorities in our 
patient cohort was only 41%, which was much lower than the proportion of ethnic minorities 
accounted for in the general population (58%). This result might indicate a disproportionally 
higher pre-ART attrition among ethnic minorities, which was supported by a study conducted in 
Yunnan
44
. Hence, it was possible that the ethnic minority PLWH in the ART program might 
have better HIV knowledge and compliance, which could lead to a better VL testing rate found 
among them. 
 
Our study had limitations. First, only three ART sites were selected in Wenshan, which might 
limit the generalizability of study results to other rural regions. Second, participants of the survey 
were only recruited from PLWH who visited the ART sites during the study period and we didn’t 
have accurate records about how many patients were screened and invited to the survey. 
Although most of the basic characteristics in the source cohort and survey cohort were 
comparable, it was possible that the results from the survey cohort could not completely 
represent the characteristics of in total source cohort. Third, only patient individual-level 
characteristics were analyzed in our study, structural level factors should be the focus of future 
studies, which should cover more regions and ART facilities.  
 
Our study results demonstrated that 58.5% of PLWH achieved VL testing at 12 months after 
ART initiation in the Wenshan area. To improve VL testing timeliness, PLWH who were young, 
at a low level of education, lived far away from ART facilities, and at advanced WHO stage 
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should be targeted. HIV healthcare decentralization to remote rural areas is highly recommended. 
UNAIDS 90-90-90 targets could only be achieved by combining efforts of patients, healthcare 
service providers, governments, and NGOs. 
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Chapter 3: Factors affecting the turnaround time of viral load testing in rural 
China: a mixed-method study in Wenshan 
 
Abstract 
Objective: To investigate current viral load (VL) testing turnaround time (TAT) in rural China, 
and to identify factors associated with prolonged TAT in each step of the VL test.  
 
Methods: A sequential explanatory mixed-method study was conducted in three ART sites and a 
central VL testing laboratory in Wenshan Prefecture, Yunnan Province of China. The study 
contained a quantitative phase and a subsequent qualitative phase. In the quantitative phase, 
individual level TAT was calculated for all VL blood samples collected in 2018. In the 
qualitative phase, in-depth interviews were conducted among healthcare providers in the ART 
sites and technicians in the central VL testing laboratory to identify factors associated with 
prolonged TAT. 
 
Results: In our study sites, a total of 2 892 VL blood samples were collected and tested during 
2018. The median TAT was 54 days (IQR: 36, 92), with a median pre-test TAT of 47 days (IQR: 
31, 81) and a median post-test TAT of 5 days (IQR: 1, 10). Factors associated with prolonged 
TAT mainly included the annual urban-to-rural labor migration, the shortage of healthcare 
professionals and lab technicians, limited VL testing instruments, and the immature reagent 
procurement system and testing results reporting system.  
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Conclusion: The current VL testing TATs in the Wenshan area were longer than those in 
developed countries and in some other low- and mid-income countries (LMICs). To address the 
challenges in each process of VL testing and shorten VL testing TAT in rural China, the local 
ART facilities, VL testing laboratories, and healthcare policymakers at all levels of government 
should collaborate and coordinate their procedures. 
 
Keywords: HIV/AIDS, viral load test, turnaround time, sequential explanatory mixed-method 
 
Introduction 
Viral load (VL) directly reflects the disease progression of HIV infection, and the VL test is the 
gold standard in antiretroviral therapy (ART) monitoring among people living with HIV 
(PLWH). To achieve the 90-90-90 targets established by the Joint United Nations Programme on 
HIV/AIDS (UNAIDS), all PLWH continuously receiving ART need to undergo routine VL tests 
and the testing results should be reported timely
1
. VL testing assays require high-level 
infrastructure, expensive testing equipment and kits, and well-trained lab technicians
2,3
. Hence, 
in low- and mid-income countries (LMIC), VL testing is only centralized in city-/prefecture- or 
higher level laboratories in most cases. 
 
In real-world settings of LMICs, centralized laboratory-based approaches are used for VL tests. 
The VL testing blood samples collected in different local ART facilities are sent to a central 
laboratory to perform VL tests. The turnaround time (TAT) of the VL test refers to the time 
interval between blood sample collection and receipt of testing results by the ART facility. The 
TAT varies considerably among different countries. Studies in well-resourced settings reported 
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the median VL testing TATs ranging from 1 to 8 days
4–6
. A study conducted in seven Sub-
Saharan countries reported that the mean TAT in each country ranged from 3 days to 50 days, 
and the mean TATs in five of the seven countries were close to or longer than 1 month
2,7
. Factors 
associated with prolonged TAT in LMICs are various. The pre-test TAT (time interval between 
blood sample collection and performing VL tests) can be influenced by weak health and 
laboratory systems, incomplete sample referral network, and a shortage of trained staff; and the 
post-test TAT (time interval between performing VL test and testing results receipt by the ART 
facilities) is mainly influenced by immature results reporting systems
2,3,8–10
.  
 
China’s National Free ART Program (NFATP) provides once-a-year free VL tests to all PLWH 
who are retained in ART for longer than 6 months. VL testing had been scaled up in China since 
2008, and by 2015 there were 181 qualified laboratories providing VL testing service, covering 
all regions of the country
11–13
. Since the VL testing laboratories are usually located in the capital 
region of a city or a province, the centralized laboratory-based strategy is used for VL tests in 
remote and rural areas. The VL testing TAT in rural China may vary from several weeks to 
months, however, there has been little published data about this issue. To investigate the current 
VL testing TAT under the centralized testing strategy in rural China, a mixed-method study was 
conducted in Wenshan Prefecture, Yunnan Province.  
 
Yunnan Province has been one of the provinces with the most serious HIV/AIDS epidemic and 
pioneered ART implementation in China
11,14
. By the end of 2016, a total of 22 laboratories in 
Yunnan were capable of VL testing
15
. Wenshan Prefecture is located in the east of Yunnan 
Province. The traffic and economy in Wenshan have not been fully developed
16–19
, and more 
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than 60% of the population is living in rural areas
18,19
. There are ten ART sites distributed in the 
eight counties of Wenshan, however, only one central VL testing laboratory located in the 
prefecture capital provides VL testing service for all PLWH in Wenshan. The aims of this study 
included: (1) to understand the current centralized VL testing strategy, (2) to calculate VL testing 
TAT and present its variation tendency during a whole calendar year; (3) to identify factors 
associated with prolonged TAT in each process of VL test.  
 
Methods 
Study sites 
Three local ART facilities (ART Site A, B, and C) and the only central VL testing laboratory in 
Wenshan Prefecture were selected as study sites. Site A is attached to a county-level general 
hospital and has the largest number of PLWH receiving ART in Wenshan. Site B is attached to 
the only prefecture-level general hospital in Wenshan, where the central VL testing laboratory is 
located. Site C is a county-level specialized HIV/AIDS care center with the third-largest number 
of PLWH in Wenshan. The number of PLWH receiving ART in Sites A, B and C accounts for 
about 41% of the total PLWH retained in care in Wenshan.  
 
Study design 
A sequential explanatory mixed-method design was used to investigate VL testing TAT and 
identify factors associated with prolonged TAT. The study contained two phases: a quantitative 
phase and a subsequent qualitative phase. In the first phase or the quantitative phase, patient-
individual level TAT was calculated for all VL blood samples collected in the three selected 
ART sites during 2018. In the second phase or qualitative phase, in-depth interviews were 
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conducted among healthcare providers in the selected ART sites and lab technicians in the 
central VL testing laboratory. 
 
Data collection for the quantitative phase 
In the quantitative phase, the dates of VL blood sample collection (T1), VL test performing (T2) 
and testing results received by the ART sites (T3) of each VL testing sample collected during 
2018 were extracted from both medical records and laboratory records. No individual-level 
identifiable information was collected. 
 
Recruitment and data collection for the qualitative phase 
In the qualitative phase, in-depth interviews were conducted among healthcare providers in ART 
sites and technicians in the VL testing laboratory. Criteria for eligible participants were (a) 
working in selected ART sites or laboratory for longer than 6 months, (b) having experience of 
VL testing related work. To fully understand the challenges in each step of the centralized VL 
testing, participants were recruited from different professions, such as physicians, lab 
technicians, administrators, nurses, and non-governmental organization (NGO) staff working in 
ART sites. The investigator first contacted a key person in each of the ART sites and the central 
VL laboratory, such as the chief physician or the laboratory director. The key person could 
participate in the study as an interviewee, and she/he could also recommend other eligible 
participants in the ART site or the laboratory. The recruitment was terminated when no new 
information was collected. Participation in our study was completely voluntary.  
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The face-to-face in-depth interviews were conducted by the investigator in an office or 
conference room at the ART sites or the laboratory. Each of the interviews was one-on-one. 
Before an interview, the investigator provided full disclosure of study procedures and contents, 
and obtained signed informed consent from each interviewee. The interviews lasted for 30 – 40 
minutes and were recorded by a recording pen. The interview started with socio-demographic 
information collection, such as age, gender, profession and working experience. Semi-
constructed interview outlines with open-ended probe questions were used in the interview. The 
interview outline towards healthcare providers included 5 main topics about the VL testing 
procedures at local ART sites: (1) environment and infrastructure, (2) ART follow-up and VL 
testing policy, (3) VL testing procedures in the ART sites, (4) ART and VL testing related work 
capacity and workload, (5) reception and utilization of VL testing results, (6) perceived 
challenges in each process of VL test and suggestions to shorten TAT. The interview outlines 
administrated to laboratory technicians included 4 topics about the VL testing procedures at the 
central laboratory: (1) environment, facilities, and reagent supplement, (2) VL testing policy, (3) 
VL testing procedures in the laboratory, (4) VL testing capacity and workload, (5) perceived 
challenges in each process of VL test and suggestions to shorten TAT. Participants who 
completed the interview received 100 Yuan (about $15) for their time and efforts. 
 
Data analysis 
In the quantitative phase, VL testing related dates (T1, T2 and T3) were first entered into Excel 
sheets, in which step the completeness and accuracy of data were checked. Then data sheets were 
transferred into a SAS data set and analyzed by SAS 9.4 software (SAS Institute, Cary, NC, US). 
The individual-level TAT, pre-test TAT, and post-test TAT were calculated for each blood 
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sample. The median of TAT, pre-test TAT and post-test TAT of each quarter during 2018 were 
presented in a table and compared by rank-sum tests. The monthly median TAT, pre-test TAT, 
and post-test TAT during 2018 were visualized by figures.  
 
In the qualitative phase, the audio records of in-depth interviews were transcribed verbatim by 
the investigator, and the transcripts were double checked to ensure the completeness and 
accuracy. Based on the interview outlines, a set of priori codes were first developed. The codes 
were then modified from the interview transcripts throughout the coding procedure. Categories 
were created based on the modified codes, and then theories were summarized from the 
categories. The original data collection and analysis were completed in Chinese, and the results 
were translated into English. ATLAS.ti5 software (Berlin, Germany) was used in data analysis. 
 
Ethics 
The study was reviewed and approved by Institutional Review Board (IRB) of University of 
California, Los Angeles (UCLA) in the U.S. and National Center for AIDS/STD Control and 
Prevention (NCAIDS), Chinese Center for Disease Center and Prevention (China CDC).  
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Results 
Centralized VL testing strategy 
Figure 3.1 describes the general procedures of centralized VL testing in Wenshan. After 
confirmation of HIV infection, all PLWH should initiate ART in a designated local ART site 
regardless of CD4 cell count
20
. PLWH go on follow-up visits to ART sites every three or four 
months for a refill of ART medications and undergoing laboratory tests. Routine VL tests are 
Figure 3.1 Flowchart of centralized viral load testing. 
ART: antiretroviral therapy; VL: viral load. a: send plasma samples to the central lab; b: send 
electronic VL testing reports. The dotted box indicates all steps involving in VL testing turnaround 
time (TAT). 
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provided once a year for patients who have been retained in care for more than 6 months. To 
undergo VL tests, patients go to local ART sites to donate blood samples, which will be 
processed and stored temporarily within the ART sites. In general, the samples are sent to the 
central VL testing laboratory once a month and the technicians in the central lab perform VL 
tests according to the order of receiving blood samples. When VL tests are completed and testing 
results are checked, electronic reports are sent back to the original ART sites in a short period of 
time. Since the VL testing rate and viral suppression rate are evaluated at the end of each 
calendar year, all the VL results should be returned to ART sites within the same calendar year 
as the blood sample collection. After receipt of VL reports, healthcare professionals in ART sites 
make clinical decisions according to the VL testing results, especially for those patients who 
have unsuppressed VL.  
 
VL blood sample collection, TAT and pre-test TAT 
Totally, 2 892 VL blood samples were collected and tested in the study sites during 2018, and all 
testing results were sent back to the original ART sites before Dec 31st, 2018. As shown in Table 
3.1, the overall median TAT of all VL tests during 2018 was 54 days (IQR: 36, 92), with a 
median pre-test TAT of 47 days (31, 81). There were 1 501 VL testing blood samples collected 
during the first quarter of 2018, accounting for 51.9% of the total annual number of samples. 
During the second quarter of 2018, the number of samples collected dramatically declined to 
356, which accounted for only 12.3% of the total annual amount. The numbers of blood samples 
collected during the third and fourth quarter were 677 (23.4%) and 358 (12.4%), respectively. 
The median pre-test TAT of the second quarter was 174 days (IQR: 173, 202), which was 
significantly longer than that of any other quarter (p<0.001). On the contrary, the median pre-test 
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TAT of the fourth quarter was 19 days (IQR: 13, 25), which was the shortest across all quarters 
(p<0.001). Figure 3.2a shows the monthly number of samples collected and the monthly median 
of the pre-test TAT. 
 
 
 
VL blood sample tested and post-test TAT 
As shown in Table 3.1, the overall median of post-test TAT for all 2 892 samples was 5 days 
(IQR: 1, 10). During the first quarter, although 1 501 samples were collected, only 784 samples 
were tested, accounting for 27.1% of the total number of samples. There were 631 (21.8%) 
samples tested during the second quarter of 2018. During the third quarter, only 290 (10.0%) 
samples were tested, however, 1 187 (41.0%) samples were tested during the fourth quarter. The 
median post-test TAT of the fourth quarter was only 1 day (IQR: 1, 3), which was significantly 
shorter than any of the other quarters (p< 0.001). Figure 3.2b shows the number of samples 
tested in each month and the corresponding monthly median post-test TAT. Notably, no VL tests 
were performed in June and August in 2018, and the numbers of samples tested in November 
sharply increased to 894, which accounted for 30.9% of the total amount in 2018.  
Table 3.1 Characteristics of viral load testing in three ART sites in Wenshan during 2018 by 
each quarter, N=2 892 
  
Sample 
collected , % 
Median pre-test 
TAT 
Sample 
tested, % 
Median post-
test TAT 
Median TAT 
Overall 2 892 (100) 47 (31, 81) 2 892 (100) 5 (1, 10) 54 (36, 92) 
  Quarter 1 1 501 (51.9) 43 (26, 57)
a
 784 (27.1) 10 (5, 11)
b
 50 (34, 64) 
  Quarter 2 356 (12.3) 174 (173, 202)
a
 631 (21.8) 7 (7, 10)
b
 175 (174, 203) 
  Quarter 3 677 (23.4) 74 (50, 117)
a
 290 (10.0) 6 (4, 23)
b
 78 (55, 118) 
  Quarter 4 358 (12.4) 19 (13, 25)
a
 1187 (41.0) 1 (1, 3)
b
 22 (15, 27) 
a: Corresponding median pre-test TAT of samples collected in the first, second, third and fourth 
quarter in 2018. b: Corresponding median post-test TAT of samples tested in the first, second, third 
and fourth quarter in 2018. 
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Interviewee characteristics 
A total of 11 healthcare providers or laboratory technicians participated in the interview, 
including 4 physicians (36.4%), a nurse (9.1%), an administrator (9.1%), 3 NOG staffs working 
in ART sites (27.3%), and 2 lab technicians (18.2%). About 36% of participants had engaged in 
VL testing related work for more than 5 years. (Table 3.2) 
 
 
Figure 3.2a Number of viral load samples collected in each month (N=2892) and the corresponding 
monthly median pre-test TAT. VL: viral load; TAT: turnaround time.  
Figure 3.2b Number of viral load samples tested in each month (N=2892) and the corresponding 
monthly median post-test TAT. VL: viral load; TAT: turnaround time. 
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Table 3.2 Background characteristics of interviewees, N=11 
Characteristics Number Percentage of total 
Age, years 
    <35 4 36.4% 
  >35 7 63.6% 
Gender 
    Female 7 63.6% 
  Male 4 36.4% 
Profession 
    Physician 4 36.4% 
  Nurse 1 9.1% 
  Administrator 1 9.1% 
  NGO staff 3 27.3% 
  Lab technician 2 18.2% 
Duration of VL test related work, 
years 
    <5 7 63.6% 
  >5 4 36.4% 
 
 
Factors associated with TAT in each key process of VL testing 
Collect VL blood samples 
More than 50% (n=1 501) of the annual total VL samples were collected in the first quarter of 
2018, which was beyond the testing capacity of the central VL laboratory. Hence, the pre-test 
TAT started to increase from March. There could be two main reasons for the unbalanced sample 
collection.  
 
First, the PLWH who were rural-to-urban migrant workers could only visit their ART sites 
during the Spring Festival vacation (usually in late January or early February). As a labor export 
province, a large number of young and mid-aged adults in Yunnan Province went to developed 
provinces to work as migrant workers and return home only during the Spring Festival every 
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year. Hence, the HIV infected migrant workers usually undergo their VL tests during the Spring 
Festival, the only time they were at home. As for the healthcare providers in the ART sites, it 
was also a priority to collect VL blood samples of those migrant patients during that period.  
 
‘About 30% to 40% of patients in our ART site are migrant workers working in other 
provinces. They don’t have to visit the ART site too frequently. We can mail ART 
medications to them. They can also undergo general laboratory tests locally and fax or 
mail testing results to us. However, they can only do VL and CD4 tests in our ART site, so 
they must visit us at least once a year. Usually, they come here during the Spring Festival 
to donate blood samples (for VL and CD4 testing). If they don’t come, we’ll call them’ (ID 
4, physician) 
 
Second, the healthcare professionals in the ART sites tended to do concentrated sample 
collection to reduce the working burden. The physician/patient ratios in the selected ART sites 
ranged from 1/600 to 1/300, which were much lower than the national standard, 1/150. As the 
current VL testing policy for patients who had been on ART for longer than 1 year and already 
achieved viral suppression, the timing of the annual VL test was not specified. To ensure the 
universal coverage of the VL test and facilitate patient management, the healthcare providers 
tended to collect their VL testing samples during the first follow-up visit of this calendar year.  
 
‘The majority of patients in our ART site have good adherence and have already achieved 
undetectable VL. For patients who were virally suppressed in 2017, I tried to collect their 
VL blood samples during the first quarter of 2018. Totally, about 60%-70% of VL blood 
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samples were collected (during the first quarter of 2018), so that we had less pressure in 
the rest of the time of 2018. (ID 8, physician)  
 
‘We always received a large number of VL plasma samples in the first three months of a 
year, which exceeded the testing capacity of our lab. Some of the samples were stored in 
our lab for longer than 1 or 2 months before VL tests. The (pre-test) TATs for samples 
collected during that period were relatively long.’ (ID 5, lab technician) 
 
Perform VL test 
After the scaling-up of VL testing, the VL blood sample can be collected at any time during the 
work hours in most of the ART sites. However, the frequencies of VL blood sample delivery and 
VL test performing are low because of low VL testing capacity.  
 
First, a shortage of VL laboratory technicians limited the VL testing capacity. After the VL 
blood sample collection, the samples were temporarily stored in the local ART sites and sent to 
the central laboratory once a month (usually in the first half of each month), which seriously 
extended the pre-test TAT. However, there were only two trained technicians in the central 
laboratory and they were also in charge of all laboratory examinations in a prefecture-level 
general hospital. They only had one week during which to perform VL tests each month.  
 
‘The frequency of VL sample delivery was determined by the central laboratory. They 
(technicians in the central VL laboratory) only do VL tests in the third or fourth week in 
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each month, so that we just send samples there before the VL testing’ (ID 1, ART site 
administrator) 
 
‘My colleague and I are in charge of all laboratory tests in our hospital. Although we need 
to perform VL tests for all blood samples from the ten ART sites across Wenshan 
Prefecture, it only accounts for 1/4 to 1/3 of our total workload. We arrange the ART sites 
to send VL samples during the first half of a month, so that we can perform VL tests in the 
second half of the month. We don’t have much time to receive samples too frequently.’ (ID 
5, lab technician) 
 
‘The VL testing samples can be stored at -80°for several weeks, hence the other urgent 
tests, such as CD4 test, have priority over the VL tests.’ (ID 11, lab technician) 
 
Second, the insufficient number of VL test instruments limited the testing capacity. There was 
only one COBAS
®
 TaqMan
®
 48 Analyzer in the central laboratory providing VL tests for all 
PLWH in Wenshan.   
 
‘We only have one VL testing instrument which can process 48 samples at a time. During 
the VL-testing week, about 500 to 600 samples can be tested. If there are still samples left, 
we have to store them until the VL-testing week in the next month.’ (ID 11, lab technician) 
 
Third, the immature reagent procurement system can seriously prolong the pre-test TAT. The 
special case in 2018 was that the central laboratory ran out of VL testing kits from June to 
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August. Only 109 samples from the three selected ART sites were tested during this period, and 
the pre-test TAT dramatically increased to over 200 days for samples collected in the second 
quarter of 2018 (Figure 3.2a). As the scaling-up of HIV testing and ART coverage, the number 
of PLWH who needed to do VL tests in 2018 grew beyond the expectation. However, the 
procurement plan for VL testing kits was made in 2017 and not updated to reflect changes in 
2018. As a result, no VL testing kits were available until September and October in 2018.  
 
‘During the period of VL testing kits shortage, a total of 2 500 VL plasma samples from all 
ten ART sites in Wenshan were stored in our lab. We began to receive new VL testing kits 
in succession from September 2018’ (ID 5, lab technician) 
 
However, the TAT for samples collected during the last quarter of 2018 was short. To evaluate 
the viral suppression rate of the year, all VL tests should be completed and all testing reports 
should be returned to ART sites by the end of 2018. Hence, the number of samples tested 
increased dramatically during November and the TAT for samples collected at the end of the 
year significantly shortened (Figure 3.2a & 3.2b). 
 
‘To return all VL testing results to the ART sites by end of last year (2018), we had to work 
overtime during October and November.’ (ID 5, lab technician) 
 
‘They (the lab technicians) might have much pressure on VL test in November and 
December of 2018, but in fact, they did a very good job. We received VL results within 
about 2 weeks after we sent samples to the laboratory.’ (ID 7, nurse) 
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Receive VL results 
After VL test performing and testing results checking, which usually took one to three days, the 
electronic testing reports were sent back to the original ART sites through a specialized ART 
information system. However, the system didn’t have a reminder function, so that the healthcare 
providers in ART sites might delay in checking and receiving electronic testing reports, which 
could be the main reason for the long post-test TAT in September (Figure 3.2b).  
 
‘In general, we checked the (VL testing) information system frequently at the end of each 
month, however, because of the testing kits shortage, we had not received VL reports for 
several months. Hence, we checked the system less frequently and might miss some reports, 
especially when the VL testing just re-started (in September 2018).’ (ID 3, physician) 
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Discussion 
Although the coverage of the VL test in China had been scaled up since 2008, the prolonged 
TAT limited the timely use of VL testing results, especially in the rural areas where a 
centralized VL testing strategy was conducted. As one of the first studies focusing on VL 
testing TAT and factors associated with prolonged TAT in China, this study identified 
important structural factors associated with prolonged TAT in each process of VL test and 
provided preliminary knowledge for further investigation on improving VL testing services 
among PLWH.       
 
Figure 3.3  Factors associated with prolonged TAT in the processes of centralized VL testing 
VL: viral load; TAT: turnaround time. The processes of centralized VL testing included (1) collect VL 
blood sample, (2) perform VL test, and (3) receive VL results.  
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Rural-to-urban migrant workers are one of the vulnerable populations to HIV. The estimated 
HIV prevalence of migrant workers in China was 0.09% in 2011 and 0.11% in 2015, which 
were approximately 60% higher than the HIV prevalence of the general population at the 
same time period
21,22
. The high mobility and more HIV risk behaviors made this population a 
potential bridge to transmit HIV to the general population
21,23–25
. Since they are highly mobile 
among provinces, HIV infected migrant workers are more likely to initiate ART in their 
hometown, where they have permanent residency and regularly go back. Among this 
population, the migration status can result in late HIV detection, late ART initiation and 
unsatisfactory ART follow-up
26–28
. Hence, they have been given attention since they were 
diagnosed as HIV positive and initiated ART. They are advised by local healthcare providers 
not to go out for work until they achieve viral suppression and are stable on ART. For those 
who have already gone out for work, the important laboratory tests, like VL tests and CD4 
count tests are generally scheduled during Spring Festival, when most of the migrant workers 
return home. 
 
The heavy working burden of healthcare providers in rural ART sites comes from two factors. 
First, the physician/patient ratios in the selected ART sites are low, ranging from 1/300 to 
1/600, which are much lower than those in some other LMICs
29,30
. Second, the PLWH in rural 
areas have low HIV-knowledge levels and are highly dependent on healthcare providers, 
which further adds to the workload of physicians. To improve work efficiency and reduce the 
working burden, healthcare providers tend to intensively collect VL testing blood samples 
during the first quarter. In addition, the VL testing TAT has been prolonged in rural areas. To 
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allow enough time for receiving testing results by the end of the calendar year, physicians 
have to collect and deliver VL testing samples as early as possible.    
 
The fundamental cause for the low frequency of sample delivery and test was insufficient VL 
testing capacity in rural areas. First, similar to the healthcare providers in rural ART sites, the 
VL testing technicians in the laboratory are also overburdened, which occurs widely in 
LMICs
3,7
. There were only two trained technicians in charge of performing VL tests for all 
PLWH in Wenshan. Although totally up to 6 900 VL plasma samples were tested in 2018 
alone, it only accounted for 1/4 to 1/3 of the technicians’ overall workload. Another reason for 
the weak VL testing capacity is insufficient VL platforms. There was only one VL testing 
instrument in Wenshan Prefecture providing service for approximate 7000 PLWH. Similarly, 
a survey in LMICs in Asia and Africa reported on average there was one VL testing 
instrument per 4 800 PLWH on ART
3,31
. To decentralize VL testing in rural areas, the point-
of-care (POC) technologies operated in ART sites are promising supplements for 
conventional lab-based testing platforms. However, POC may further increase the burden of 
healthcare providers in local ART sites, and the performance of POC tests are still to be 
validated
3,9
. 
 
A mature reagent procurement system should have the ability to forecast the VL testing kits 
needed in the next year and cope with any unexpected situation. The shortage of VL testing 
kits is not uncommon, but the problem is especially noticeable during 2018. The VL testing 
demand in 2018 was higher than expected. HIV testing had been continuously scaled up and 
HIV-related mortality remained stable, hence the number of PLWH continuously increased
32–
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34
. In addition, the implementation policy requiring immediate ART was made in 2016
20,35
, 
which directly increased the demand of VL testing. The procurement plan of VL testing kits 
for 2018 was made by a provincial HIV/AIDS care institution during 2017 and no timely 
adjustments were made subsequently, which directly led to the shortage of VL testing kits 
from June to August in 2018.  
 
There are some limitations to our study. First, Wenshan Prefecture was the only study location 
selected in our study and no comparison groups were included. The VL testing strategy and 
TAT could vary by different regions, but we were not able to compare the situations in 
Wenshan with other rural areas in China. Second, the single study location might limit the 
generalizability of our study results. The factors identified in Wenshan Prefecture might not 
represent the situations in other rural regions. Third, we only focused on VL testing TAT 
during 2018, so that the TAT variation trend in recent years could not be investigated. To 
further investigate VL testing TAT and factors associated with prolonged TAT, larger-scaled 
studies covering more regions, different VL testing strategies, and a longer study period are 
needed. 
 
In conclusion, the current VL testing TAT in Wenshan areas is still suboptimal, and 
challenges exist in each step of the centralized VL testing procedures. There is a need to 
improve current VL testing service and to shorten TAT by increasing the numbers of 
healthcare professionals and lab technicians undertaking ART and VL related works. It is also 
suggested to strengthen the relevant professional training, improve the laboratory network 
construction, ensure sufficient testing reagent supplies, and improve the ART information 
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system. The application of new POC VL testing technologies in local ART sites and a flexible 
ART referral system among migrant PLWH should also be explored in rural China. To 
achieve the 90-90-90 goals, it is very important to raise the VL testing efficiency and 
effectively use VL testing results. The local ART facilities, VL testing laboratories, and 
healthcare policymakers at all levels of government should collaborate and coordinate their 
procedures.  
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Chapter 4: Is active concern for viral load testing results associated with 
better antiretroviral therapy response among people living with HIV? A 
clinic-based study in Yunnan Province, China 
 
Abstract 
Background: In low- and mid-income countries (LMIC), where the viral load (VL) testing 
system is not well developed, the HIV-infected patients are not informed of the VL testing 
results until long after VL blood sample collection. Hence, some patients take the initiative to 
ask about VL testing results before patient notification.  
 
Objective: To investigate the association between actively asking about VL testing results and 
antiretroviral therapy (ART) outcomes among people living with HIV (PLWH) in rural China. 
 
Methods: A clinic-based study was conducted in three ART facilities in Wenshan Prefecture, 
Yunnan Province of China. PLWH who initiated ART between Jan 1, 2015 and Dec 31, 2016 in 
these three facilities were recruited to participate in a survey from Jan to Mar in 2019, which 
collected information about socio-demographic characteristics, VL testing experience, VL-
related knowledge, and family/social support using structured questionnaire. In addition, clinical 
characteristics and VL testing results were extracted from medical records. The rates (%) of viral 
suppression and sustained viral suppression (SVS) at the end of 2018 were calculated. 
Descriptive analyses and logistic regressions were conducted to investigate the association 
between actively asking about VL testing results and SVS, and to identify other factors 
associated with SVS. 
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Results: A total of 264 PLWH participated in the survey. The median age was 41.5 years (IQR 
32.1-50.6), and 58.0% of them (n=153) were male. Most of the participants were infected with 
HIV by heterosexual contact (95.5%, n=252), and the baseline CD4 count at ART initiation was 
321/μL (IQR: 210-452). The median ART duration of all participants was 3.0 years (IQR: 2.4-
3.5). Among the participants, 58.3% (n=154) reported they had ever taken the initiative to ask 
about VL testing results before patient notification. By Dec 31, 2018, 95.1% of participants 
(n=251) had VL lower than 200 copies/mL, and 61.0% (n=161) had achieved SVS for 18 
months. In the multivariable analysis, PLWH who had ever proactively asked about VL testing 
results were 3 times more likely to achieve SVS compared with those who had never asked 
(aOR=3.08, 95% CI=1.52-6.26). Other factors associated with SVS included baseline CD4 
count, VL-related knowledge, support from non-governmental organizations (NGO), age, and 
time interval from HIV diagnosis to ART initiation.  
 
Conclusions: Good virological outcomes among PLWH retaining in clinical care were observed 
in rural China. Under the circumstance of resource-limited settings, PLWH should be 
encouraged to actively communicate with healthcare providers. Larger-scaled follow-up studies 
covering more regions and participants are needed in the future.     
 
Keywords: HIV/AIDS, antiretroviral therapy, viral load test, sustained viral suppression, patient 
notification 
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Introduction 
Viral load (VL) is the most important indicator of HIV disease progression and antiretroviral 
therapy (ART) response
1–4
. The Joint United Nations Programme on HIV/AIDS (UNAIDS) 
established 90-90-90 targets, which required 90% of people living with HIV (PLWH) receiving 
ART to achieve viral suppression
5
. Good viral suppression rates have been observed among 
PLWH who are continually taking ART in low- and mid-income countries (LMIC)
6
. A study 
conducted in rural east Africa
7
 reported that 90% of PLWH treated had viral suppression 
(VL<500 copies/mL). Nationwide cohort studies in China
8,9
 also reported that the rates of viral 
suppression (VL<400 copies/mL) ranged from 89% to 91% among PLWH receiving ART. Since 
ART is a life-long process, it is important to continuously keep VL at an undetectable level. 
Sustained viral suppression (SVS), which focuses on the long-term ART response has also been 
investigated. Studies
10–12
 conducted in the United States reported that the proportion of SVS 
among PLWH receiving HIV clinical care had increased from 45% in 2001 (SVS: sustained 
VL<400 copies/mL) to 68% in 2013 (SVS: sustained VL<200 copies/mL), and the increase was 
particularly evident in the young PLWH group (18-24 years). In an ethnic minority region of 
rural China, the SVS among PLWH who were receiving ART and had VL measurements in 2013 
was about 41% (sustained VL< 50 copies/mL)
13
. 
 
China’s National Free Antiretroviral Therapy Program (NFATP) provides free ART and relevant 
laboratory tests to all PLWH. After at least 6-month successive ART, a free VL test is provided 
for each patient once a year
14
. Generally, PLWH visit local ART sites every three to four months 
for routine follow-up visits, during which they can refill ART medications and undertake 
necessary laboratory tests. Like other LMICs, where the VL testing service has not been fully 
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developed, a laboratory-based centralized VL testing strategy is used in China
15
. Patients go to 
local ART sites to donate blood samples for VL testing, which are sent to and tested in a central 
laboratory periodically. After performing VL tests, the testing reports are sent back to the local 
ART sites, so that healthcare providers can implement clinical interventions according to the 
reports and inform patients of the testing results. It usually takes several weeks to months 
between blood sample collection and testing reports sent back to the original ART sites, so that 
the patients can only be informed even later
16,17
. Additionally, there has been no uniform system 
or policy across the country about how and when to inform patients of VL testing results. Hence, 
some patients tend to take the initiative to ask about the VL testing results before the patient 
notification. Studies
18–22
 have reported that the capacity of obtaining healthcare information and 
good communication with healthcare providers are important for PLWH to have better ART 
adherence and achieve optimal virological outcomes. Therefore, it is reasonable to hypothesize 
that patients who proactively communicate with healthcare providers and ask about VL testing 
results can be more likely to have better ART outcomes. To investigate the association between 
actively asking about VL testing results and SVS among PLWH receiving ART in rural China, a 
cross-sectional study was conducted in Wenshan Prefecture, Yunnan Province. 
 
Yunnan Province has been one of the provinces with the most serious HIV/AIDS epidemic and 
which pioneered ART implementation in China
23,24
. Wenshan Prefecture is located in the eastern 
mountainous region of Yunnan. The economy and education in Wenshan have not been fully 
developed, and more than 60% of the population are living in rural areas
25,26
.  The ten ART sites 
are distributed in the eight counties of Wehshan and provide ART-related service to all PLWH 
across the prefecture. Generally, the PLWH are informed of VL testing results during their next 
92 
 
routine follow-up visits. However, when the patients take the initiative to ask about VL testing 
results in person or by phone, the healthcare providers will provide and explain the results to 
them immediately, if the testing results have already been received by the ART sites. For a small 
number of patients who have obviously elevated VL testing results, the healthcare providers tend 
to contact them and provide adherence support as soon as possible. The specific aims of this 
study include: (1) to calculate the rates (%) of viral suppression and SVS at the end of 2018 
among PLWH in Wenshan; (2) to investigate the association between actively asking about VL 
results and SVS; (3) to identify other factors associated SVS.  
 
Methods 
Study sites 
Three ART sites (Site A, B, and C) in Wenshan Prefecture were selected as study sites. Site A is 
attached to a county-level general hospital and has the largest number of PLWH receiving ART 
in Wenshan. Site B is attached to the only tertiary-level (the highest level in China) hospital in 
Wenshan and accepts PLWH coming from the whole prefecture. Site C is a county-level 
specialized HIV/AIDS care center with the third largest number of PLWH in Wenshan. The total 
number of PLWH retaining in care at the three ART sites accounts for more than 40% of the 
whole PLWH population in the Wenshan Prefecture. 
 
Study design 
A clinic-based study was conducted among PLWH who initiated ART between Jan 1, 2015 to 
Dec 31, 2016 in the three study sites. Information about socio-demographic characteristics, VL 
testing experience, VL-related knowledge, and family/social support, was collected from a 
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survey using a structured questionnaire. Basic clinical characteristics and VL testing results were 
extracted from medical records. Logistic regression models were conducted to assess the 
association between actively asking about VL testing results and SVS. 
 
Enrollment  
The survey was conducted from Jan to Mar 2019. During the 3-month study period, patients who 
went to the ART sties A, B and C for routine follow-up visits or education meetings were 
screened for eligibility. The eligibility criteria included (a) initiated ART from Jan 1, 2015 to 
Dec 31, 2016, (b) initiated ART in Site A, B, and C, (c) were aged≥18 years when initiated ART, 
(d) had remained in care for more than 6 months. When patients visited the study sites, 
healthcare providers in the ART sites would first check their medical records for eligibility. 
Since PLWH was a sensitive population, healthcare providers in the ART sites were in charge of 
making the initial screen and contact to patients on behalf of the investigator. For eligible 
patients, the healthcare providers then simply introduced the study and invited them to 
participate in the survey.  If the potential participants agreed to participate, they would be 
referred to the investigator. The investigator then double-checked the eligibility and conducted a 
questionnaire survey to the eligible ones on the same day of recruitment (Figure 4.1).  
 
Data collection 
There were two main data sources: structured questionnaire surveys and medical records.  Oral 
informed consent was obtained before the survey. After being recruited, participants filled out 
the questionnaire under the investigator’s guidance. If the participant was not able to read, the 
investigator did a face-to-face survey and filled out the questionnaire according to the 
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participant’s answers. The patient ID was collected to link survey data to medical records, and it 
was deleted once data were linked. It took 10-15 minutes to complete a questionnaire. After the 
survey, each participant received a gift equivalent to 20 Yuan (about 3 USD). 
 
The questionnaire consisted of four parts. The first part was socio-demographic information, 
including gender, age, and education level. The second part was about the experience of VL 
testing. The participants were asked whether they only underwent VL tests in the same sites in 
which they received ART  (yes/no/I don’t know), whether they only underwent VL tests during 
routine follow-up visits (yes/no/I don’t know), how did they evaluate the current patient 
notification strategy of VL testing results (good/fair/too slow/I don’t know), had they ever taken 
the initiative to ask about VL testing results before patient notification (yes/no/ I don’t know 
what is viral load test), and what was their overall satisfaction with the ART service 
(good/fair/poor). The variable of whether having ever taken the initiative to ask about VL testing 
results was the main exposure of our study. Both the participants who answered “no” and “I 
don’t know” were regarded as “never asked”. The third part was the awareness of VL-related 
knowledge. There were 5 questions about VL or VL test, including the frequency of routine VL 
test, the optimal result of VL test, the most important reason for ART failure, whether a patient 
with successive optimal VL results needs to continue ART, and whether a patient with 
successive optimal VL results can infect others. Each question was worth one point. The total 
score of each participant and the median score for the survey population were calculated and a 
new binary variable indicating higher (> median score) or lower score (≤ median score) was 
generated accordingly. The last question for this part was the source of the knowledge (learning 
from healthcare providers/self-studying/learning from other patients/and other ways). The fourth 
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part of the questionnaire was about the family support and social support for the patients. The 
questions included the patient’s marital status, the HIV status of the patient’s spouse or partner, 
the current living status of the patient (living alone/living only with the spouse or partner/living 
with other family members). If the patients were not living alone, they would be further asked 
about whether they had disclosed their HIV status to people who were living with them and 
whether they had got support from people who were living with them. The last question was 
whether they had ever got support from non-governmental organizations (NGOs) (got much 
support/got some support/never got any support).   
  
After completing the questionnaire survey, the participants’ clinical characteristics and VL 
testing results were extracted from medical records in the ART sites. The clinical characteristics 
included the HIV transmission route, date of HIV diagnosis, date of ART initiation, baseline 
CD4 cell count, and baseline ART regimen. The date and result of each VL test between ART 
initiation and Dec 31, 2018 were extracted and the SVS rates (%) by Dec 31, 2018 were 
calculated. All data were extracted by healthcare providers working in the three study sites. 
 
The measurement of sustained viral suppression (SVS) 
In our study, viral suppression or virally suppressed status was defined as undetectable HIV VL 
or VL<20 copies/mL. SVS was defined as maintaining viral suppression for 18 months by Dec 
31, 2018, i.e. maintaining viral suppression from Jul 1, 2017 to Dec 31, 2018. Specifically, the 
following two situations could be regarded as SVS: (1) patients who had two or more VL tests 
during that 18-month period and all testing results were virally suppressed; (2) patients who had 
only one VL test during that 18-month period and the testing result was virally suppressed, 
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meanwhile, the last VL test prior to that 18-month period was also virally suppressed. All other 
situations were considered as a failure to SVS. 
 
Statistical analysis 
Descriptive analyses were conducted to describe the characteristics of our survey population, 
including demographic characteristics, basic clinical characteristics, family/social support, and 
VL-related knowledge. The results of descriptive analyses were presented by the different 
statuses of the exposure, i.e. whether having ever proactively asked about VL testing results 
before patient notification. Categorical variables were compared by the Chi-square test, and 
continuous variables were compared by the Wilcoxon test. Stratified analyses of each covariate 
were conducted for the exposure. The associations between the exposure and SVS were 
estimated by univariate and multivariate logistic regression models. Covariates included in the 
multivariate models were selected based on the results of univariate analyses (p<0.1) and prior 
knowledge. Crude odds ratios (cOR) and adjusted odds ratios (aOR) were presented with 95% 
confidence intervals (95% CI) and p-values. Furthermore, sensitivity analyses were conducted. 
First, the definition of SVS was changed from maintaining viral suppression for 18 months to 
maintaining viral suppression for 12 months; second, a new multivariate analysis was conducted 
among a sub-group, in which participants who had no awareness of VL test were excluded. Data 
were analyzed using SAS 9.4 software (SAS Institute, Cary, NC, US) 
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Ethics 
The study was reviewed and approved by Institutional Review Board (IRB) of University of 
California, Los Angeles (UCLA) in the U.S. and National Center for AIDS/STD Control and 
Prevention (NCAIDS), Chinese Center for Disease Center and Prevention (China CDC).  
 
Results 
Recruitment 
Figure 4.1 shows the procedures of participant recruitment for the survey. Patients who visited 
the three study sites during the 2019 January to March were first screened for eligibility by 
healthcare providers working in the ART sites. The eligible individuals were invited to 
participate in the survey and those who accepted the invitation were referred to the investigator. 
A total of 293 patients passed the preliminary screening, agreed to participate in the survey and 
were referred to the investigator. Twelve of the 293 patients were referred twice so that 281 
patients were double-checked for eligibility by the investigator. Seventeen patients were ruled 
out during the double-check procedure and finally, 264 (90.1%) of patients participated in the 
survey. 
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Participants’ characteristics 
As shown in Table 4.1, the median age of all 264 participants was 41.5 years (IQR 32.1-50.6), 
and 58.0% of them (n=153) were male. The proportion of participants who were illiterate or had 
only elementary school education was up to 47.2% (n=124). Most participants were infected 
Figure  4.1  Flowchart: participants recruitment procedures of the survey  
ART=antiretroviral therapy. Dropout was defined as loss to follow-up or discontinuation ART.  
*: The numbers of patients who were preliminarily screened by the healthcare providers and invited to 
participate in the survey was not recorded.  
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with HIV by heterosexual contacts (95.5%, n=252), and 61.4% (n=162) of them had initiated 
ART within 1 month after HIV diagnosis. The median baseline CD4 count at ART initiation was 
321/μL (IQR: 210-452) and the two main baseline ART regimens were 
Tenofovir(TDF)/Lamivudine(3TC)/Efavirenz(EFV) and zidovudine(AZT)/3TC/EFV, which 
accounted for 39.4% (n=104) and 34.1% (n=90), respectively. By Dec 31, 2018, the median 
ART duration of all participants was 3.0 years (IQR: 2.4-3.5).  
 
All of the 264 participants had at least one VL test after ART initiation. Among them, 86.0% 
(n=227) reported they had undergone all VL tests in the same ART sites and 48.1% (n=127) of 
them had undergone VL tests only during routine follow-up visits. Only 20.5% (n=54) of 
participants thought the current notification strategy of VL testing results was good. A total of 
58.3% (n=154) of participants had ever taken the initiative to ask about the VL testing results, 
and 41.7 % (n=110) had never asked. Among these 110 participants, 40% (n=44) had no 
awareness of VL test. Overall, 89.4% (n=236) of participants reported they were very satisfied 
with the current ART service.   
 
The socio-demographic and clinical characteristics of the survey population were also compared 
by the status of whether they had asked about the VL testing results before patient notification 
(Table 4.1). Patients who were more likely to ask about VL testing results tended to have higher 
education levels (p<0.001), received ART in Site B (p<0.001), and use TDF/3TC/EFV as the 
baseline ART regimen (p<0.001). 
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Table 4.1 The socio-demographic and clinical characteristics of the participants by the status of 
whether they had ever asked about VL testing results before patient notification, N=264. 
Variables 
All participants 
(n%) 
Ever asked about VL testing results before 
patient notification 
Yes (n%) No (n%) P-value 
Overall 264 (100) 154 (100) 110 (100) 
 
Gender 
    
  Male 153 (58.0) 89 (57.8) 64 (58.2) 0.950 
  Female 111 (42.0) 65 (42.2) 46 (41.8) 
 
Age at ART initiation, years 
    
Median (IQR) 41.5 (32.1, 50.6) 40.9 (31.9, 49.6) 42.7 (32.3, 51.4) 0.507 
  18-30 52 (19.7) 29 (18.8) 23 (20.9) 0.587 
  30-45 110 (41.7) 69 (44.8) 41 (37.3) 
 
  45-60 72 (27.3) 41 (26.6) 31 (28.2) 
 
  >60 30 (11.4) 15 (9.7) 15 (13.6) 
 
Education level 
    
  Illiteracy & elementary school 124 (47.2) 57 (37.3) 67 (60.9) <0.001 
  Middle school 89 (33.8) 58 (37.9) 31 (28.2) 
 
  High school & above 50 (19.0) 38 (24.8) 12 (10.9) 
 
ART site 
    
  Site A 85 (32.2) 22 (14.3) 63 (57.3) <0.001 
  Site B 84 (31.8) 72 (46.7) 12 (10.9) 
 
  Site C 95 (36.0) 60 (39.0) 35 (31.8) 
 
Time of ART initiation 
    
  2015 128 (48.5) 72 (46.8) 56 (50.9) 0.505 
  2016 136 (51.5) 82 (53.2) 54 (49.1) 
 
Route of HIV transmission 
    
  Heterosexual behaviors 252 (95.5) 147 (95.5) 105 (95.5) 1.000 
  Other 12 (4.5) 7 (4.5) 5 (4.5) 
 
Interval between HIV diagnosis 
and ART initiation     
  Median (IQR), days 13 (5, 161) 11 (5, 102) 17 (5, 239) 0.363 
  <7 days 108 (40.9) 65 (42.2) 43 (39.1) 0.726 
  7 days - 1 month 54 (20.5) 33 (21.4) 21 (19.1) 
 
  1 month - 1 year 56 (21.2) 29 (18.8) 27 (24.5) 
 
  >1 year 46 (17.4) 27 (17.5) 19 (17.3) 
 
CD4 cell count/μL at ART 
initiation     
  Median (IQR) 321 (210, 452) 327 (212, 451) 313 (202, 452) 0.823 
  <200 72 (27.3) 42 (27.3) 30 (27.3) 0.602 
  200-350 82 (31.1) 46 (29.9) 36 (32.7) 
 
  350-500 63 (23.9) 41 (26.6) 22 (20.0) 
 
  >500 47 (17.8) 25 (16.2) 22 (20.0) 
 
Baseline ART regimen 
    
  TDF+3TC+EFV 104 (39.4) 75 (48.7) 29 (26.4) <0.001 
  AZT+3TC+EFV 90 (34.1) 44 (28.6) 46 (41.8) 
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  LPV/r+other drugs 29 (11.0) 19 (12.3) 10 (9.1) 
 
  Other combinations 41 (15.5) 16 (10.4) 25 (22.7)   
VL: viral load; ART: antiretroviral therapy; TDF: tenofovir; 3TC: lamivudine; EFV: efavirenz; AZT: 
zidovudine; LPV/r: lopinavir/ritonavir 
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The results of the five questions about VL-related knowledge are shown in Table 4.2. The 
accuracy rate for each question was 45.1%, 35.6%, 66.3%, 79.2% and 30.7%, respectively. 
Patients who had ever proactively asked about VL testing results tended to have a higher 
accuracy rate for each of the five questions (p<0.001, p<0.001, p<0.001, p<0.001 and p=0.018, 
respectively). The total score for the five questions ranged from 0 to 5, and the median of the 
total score was 3 points (IQR: 1.5 - 4). The median score of patients who had ever asked about 
VL testing results was significantly higher than those who had never asked (p<0.001). As the 
total score went up, the patients were also more likely to asked about VL testing results (0 point: 
10.3%, 1 point: 29.6%, 2 points: 59.7%, 3 points: 69.8%, 4 points: 79%, and 5 points: 84.6%, 
Ptrend<0.001). A total of 67.8% (n=179) of participants reported they learned this knowledge only 
from healthcare providers in the ART sites, and 32.2% (n=85) had other ways to learn.
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Table 4.2 Awareness of VL testing-related knowledge by the status of whether they had ever 
asked about VL testing results before patient notification, N=264 
Questions 
All 
participants 
(n%) 
Ever asked about VL testing results 
before patient notification 
Yes (n%) No (n%) P-value 
Overall 264 (100) 154 (100) 110 (100) 
 
1) What's the frequency of free VL test? 
    
  Correct 119 (45.1) 93 (60.4) 26 (23.6) <0.001 
  Wrong 145 (54.9) 61 (39.6) 84 (76.4) 
 
2) What's the optimal result of VL test? 
    
  Correct 94 (35.6) 79 (51.3) 15 (13.6) <0.001 
  Wrong 170 (64.4) 75 (48.7) 95 (86.4) 
 
3) What's the most important reason for 
ART failure?     
  Correct 175 (66.3) 126 (81.8) 49 (44.6) <0.001 
  Wrong 89 (33.7) 28 (18.2) 61 (55.4) 
 
4) If a patient has got the optimal viral 
load for several successive years, does 
he/she need to continue ART? 
    
  Correct 209 (79.2) 139 (90.3) 70 (63.4) <0.001 
  Wrong 55 (20.8) 15 (9.7) 40 (36.4) 
 
5) If a patient has got the optimal viral 
load for several successive years, can 
he/she still infect others?  
    
  Correct 81 (30.7) 56 (36.4) 25 (22.7) 0.018 
  Wrong 183 (69.3) 98 (63.4) 85 (77.3) 
 
Total score 
    
  Median (IQR) 3.0 (1.5, 4.0) 3.0 (2.0, 4.0) 2.0 (0, 3.0) <0.001 
  Lower score (<3) 123 (46.6) 46 (29.9) 77 (70.0) <0.001 
  Higher score (>=3) 141 (53.4) 108 (70.1) 33 (30.0) 
 
Source of the knowledge 
    
  Only learning from healthcare providers 
in the ART site 
179 (67.8) 90 (58.4) 89 (80.9) <0.001 
  Other Sources (including learning from 
healthcare providers, self-study, learning 
from other PLWH, learning from NGOs, 
etc.) 
85 (32.2) 64 (41.6) 21 (19.1)   
VL: viral load; ART: antiretroviral therapy; PLWH: people living with HIV; NGO: non-governmental 
organizations 
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Table 4.3 showed the family and social support for the participants. Among all the participants, 
68.3% (n=179) were married, and 31.3% (n=82) had a HIV positive spouse. Most of the 
participants (76.9%, n=203) were living with their spouse or other family members, and only 
23.1% (n=61) were living alone. Among the 203 participants who are not living alone, 84.7% 
(n=172) had disclosed their HIV status to family members. And among those 172 participants, 
89.5% (n=154) reported they were supported by their family members. In addition to the family 
support, 70.5% (n=186) of the total 264 participants reported they had got help from NGOs to 
some extent. Participants who had ever asked about VL testing results tended to be supported 
more by NGOs (p<0.001).
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Table 4. 3 The family and social support for the participants by the status of whether they had 
ever asked about VL testing results before patient notification, N=264. 
Variables 
  
All 
participants 
(n%) 
Ever asked about VL testing 
results before patient notification 
  Yes (n%) No (n%) P-value 
Overall 
 
264 (100) 154 (100) 110 (100) 
 
Current marital status 
     
  Single 
 
83 (31.7) 49 (31.8) 33 (30.6) 0.718 
  Married, with an HIV negative spouse 
 
97 (37.0) 54 (35.1) 43 (39.8) 
 
  Married, with an HIV positive spouse   82 (31.3) 51 (33.1) 32 (29.6)   
Living status 
     
  Live alone  
 
61 (23.1) 31 (20.1) 30 (27.3) 0.278 
  Live with a spouse/partner 
 
81 (30.7) 52 (33.8) 29 (26.4) 
 
  Live with family members (including the 
spouse/partner)  
122 (46.2) 71 (46.1) 51 (46.4) 
 
Among the participants NOT live alone 
(n=203)      
  Do people living with you know your HIV 
status?      
    Yes, they all know 
 
107 (52.7) 64 (52.0) 43 (53.8) 0.408 
    Yes, some of them know 
 
65 (32.0) 37 (30.1) 28 (35.0) 
 
    No, they don't know 
 
31 (15.3) 22 (17.9) 9 (11.2) 
 
If people living with you know your HIV 
status (n=172),      
do they provide you any support about ART?  
     
    Yes, much help 
 
74 (43.0) 46 (45.5) 28 (39.4) 0.727 
    Yes, some help 
 
80 (46.5) 45 (44.6) 35 (49.3) 
 
    Not at all   18 (10.5) 10 (9.9) 8 (11.3)   
Support from NGOs 
     
  Got much support 
 
110 (41.7) 81 (52.6) 29 (26.4) <0.001 
  Got some support 
 
76 (28.8) 40 (26.0) 36 (32.7) 
 
  Never got any support   78 (29.5) 33 (21.4) 45 (40.9)   
VL: viral load; ART: antiretroviral therapy; NGO: non-governmental organizations 
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VL status by Dec 31, 2018 
By Dec 31, 2018, 95.5% (n=252) of the 264 participants’ VL testing results fell below 1000 
copies/mL, 95.1% (n=251) fell below 200 copies/mL, and 85.6% (n=226) fell below 20 
copies/mL or were undetectable, i.e. at viral suppression status. A total of 61.0% (n=161) 
participants had achieved SVS status for 18 months. 
 
Stratified analysis 
As shown in Table 4.4, the SVS rate (%) among patients who had ever asked about VL testing 
results before the patient notification was significantly higher than those who never asked 
(66.9% vs. 52.7%, p=0.02). Participants with a higher education level (p<0.1) and who initiated 
ART in 2015 (p<0.1) were more likely to have SVS status at the end of 2018. Meanwhile, 
participants who were older than 60 years (p<0.1), receiving ART in Site C (p<0.1), and had 
baseline CD4 < 200 count/μL (p<0.1) were less likely to have SVS status. The SVS rates (%) for 
participants who had ever asked about VL testing results and who had never asked about VL 
testing results were different by gender (Male: p=0.002), age group (>60: p=0.003), education 
level (Middle school: p=0.009), ART sites (Site A: p=0.004), time of ART initiation (2016: 
p=0.029), baseline ART regimen (TDF+3TC+EFV: p=0.049), VL knowledge score (Lower: 
p=0.022), living status (Live alone: p=0.014) and NGO supports (Some support: p=0.012).   
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Table 4.4 Stratified analysis of SVS for 18 months by whether they had ever asked about VL 
testing results before patient notification, N=264 
Variables 
Participants achieved SVS for 18 months, (%) 
Overall 
Ever asked about VL testing results 
before patient notification 
Yes No P-value 
Overall 161 (61.0) 103 (66.9) 58 (52.7) 0.020 
Gender 
    
  Male 92 (60.1) 63 (70.8) 29 (45.3) 0.002 
  Female 69 (62.2) 40 (61.5) 29 (63.0) 0.872 
Age at ART initiation, years 
    
  18-30 36 (69.2)* 22 (75.9) 14 (60.9) 0.245 
  30-45 68 (61.8)* 45 (65.2) 23 (56.1) 0.341 
  45-60 45 (62.5)* 26 (63.4) 19 (61.3) 0.854 
  >60 12 (40.0)* 10 (66.7) 2 (13.3) 0.003 
Education level 
    
  Illiteracy & elementary school 67 (54.0)* 32 (56.1) 35 (52.2) 0.664 
  Middle school 59 (66.3)* 44 (75.9) 15 (48.4) 0.009 
  High school & above 35 (70.0)* 27 (71.1) 8 (66.7) 0.773 
ART site 
    
  Site A 56 (65.9)* 20 (90.9) 36 (57.1) 0.004 
  Site B 56 (66.7)* 50 (69.4) 6 (50.0) 0.186 
  Site C 49 (51.6)* 33 (55.0) 16 (45.7) 0.382 
Time of ART initiation 
    
  2015 85 (66.4)* 51 (70.8) 34 (60.7) 0.229 
  2016 76 (55.9)* 52 (63.4) 24 (44.4) 0.029 
Interval between HIV diagnosis and 
ART initiation     
  <7 days 74 (68.5) 48 (73.9) 24 (55.8) 0.052 
  7 days - 1 month 30 (55.6) 19 (57.6) 10 (47.6) 0.474 
  1 month - 1 year 37 (66.1) 21 (72.4) 16 (59.3) 0.299 
  >1 year 23 (50.0) 15 (55.6) 8 (42.1) 0.369 
CD4 cell count/μL at ART initiation 
    
  <200 36 (50.0)* 25 (59.5) 11 (36.7) 0.059 
  200-350 57 (69.5)* 36 (78.3) 21 (58.3) 0.052 
  350-500 36 (57.1)* 24 (58.5) 12 (54.5) 0.760 
  >500 32 (68.1)* 18 (72.0) 14 (63.6) 0.539 
Baseline ART regimen 
    
  TDF+3TC+EFV 69 (66.4) 54 (72.0) 15 (51.7) 0.049 
  AZT+3TC+EFV 49 (54.4) 25 (56.8) 24 (52.2) 0.658 
  LPV/r+other drugs 20 (69.0) 14 (73.7) 6 (60.0) 0.449 
  Other combinations 23 (56.1) 10 (62.5) 13 (52.0) 0.509 
Total score of VL related knowledge 
    
  Lower 77 (62.6) 33 (71.7) 44 (57.1) 0.105 
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  Higher 84 (59.6) 70 (64.8) 14 (42.4) 0.022 
Current marital status 
    
  Single 48 (57.8) 32 (62.8) 16 (50.0) 0.252 
  Married, with an HIV negative spouse 57 (58.8) 35 (64.8) 22 (51.2) 0.175 
  Married, with an HIV positive spouse 55 (67.1) 36 (73.5) 19 (57.6) 0.133 
Living status 
    
  Live alone 36 (59.0) 23 (74.2) 13 (43.3) 0.014 
  Live with a spouse/partner 52 (64.2) 35 (67.3) 17 (58.6) 0.434 
  Live with family members (including 
the spouse/partner) 
73 (59.8) 45 (63.4) 28 (54.9) 0.346 
Support from NGOs 
    
  Got much support 68 (61.8) 52 (64.2) 16 (55.2) 0.391 
  Got some support 49 (64.5) 31 (77.5) 18 (50.0) 0.012 
  Never got any support 44 (56.4) 20 (60.6) 24 (53.3) 0.522 
SVS: sustained viral suppression; ART: antiretroviral therapy; TDF: tenofovir; 3TC: lamivudine; 
EFV: efavirenz; AZT: zidovudine; LPV/r: lopinavir/ritonavir; NGO: non-governmental 
organization; 
*: the rates of 18-month SVS were significantly different within categories of this characteristic, 
p<0.1; 
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Factors associated with SVS 
As shown in Table 4.5, after controlling for all potential confounders and effect measure 
modifiers, the odds of SVS for participants who had ever asked about VL testing results was 
higher than 3 times (aOR=3.08, 95%CI=1.52-6.26) of those who had never asked. Participants 
who had higher baseline CD4 count (200-350/μL vs. <200/μL: aOR=3.32, 95% CI=1.47-7.53; 
>500/μL vs. <200/μL: aOR=2.90, 95% CI=1.13-7.91), had got support from NGOs (Much 
support vs. No support: aOR= 2.54, 95% CI=1.07-6.02), and had lower score for VL-related 
knowledge (Lower score vs. Higher score: aOR=4.37, 95% CI=1.85-10.32) were more likely to 
achieve SVS. In addition, participants who were older than 60 years (>60 vs. 18-30: aOR=0.19, 
95% CI=0.06-0.65), initiated ART later than 1 year after HIV diagnosis (>1 year vs. <7 days: 
aOR=0.24, 95% CI=0.10-0.60), and were receiving ART in Site C (Site C vs. Site A: aOR=0.28, 
95% CI=0.10-0.76) were less likely to have SVS. When the definition of SVS was changed from 
maintaining at viral suppression for 18 months to 12 months, the experience of asking about VL 
testing results was still strongly associated with SVS (aOR=2.76, 95% CI=1.37-5.55) 
(Supplement Table 4.1). After excluding the participants who had no awareness of VL test 
(n=44), a positive association between asking about VL results and SVS was still observed 
(OR=5.7, 95%CI=2.4-13.5).
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Table 4.5 Factors associated with sustained viral suppression for 18 months by logistic 
regression modeling, N=264 
Variable 
Sustained 
viral 
suppression 
(n%) 
Univariate model 
 
Multivariate model 
cOR (95% CI) P-value   aOR (95% CI) 
P-
value 
Overall 161 (100) 
     
Ever asked about VL testing 
results before patient 
notification 
      
  Yes 103 (64.0) 1.81 (1.10, 3.00) 0.021 
 
3.08 (1.52, 6.26) 0.002 
  No 58 (36.0) -- 
  
-- 
 
Gender 
      
  Male 92 (57.1) 0.92 (0.56, 1.52) 0.738 
 
1.12 (0.57, 2.18) 0.739 
  Female 69 (42.9) -- 
  
-- 
 
Age at ART initiation, years 
      
  18-30 36 (22.4) -- 
  
-- 
 
  30-45 68 (42.2) 0.72 (0.36, 1.45) 0.359 
 
0.81 (0.35, 1.91) 0.633 
  45-60 45 (28.0) 0.74 (0.35, 1.58) 0.438 
 
1.21 (0.46, 3.19) 0.707 
  >60 12 (7.5) 0.30 (0.12, 0.76) 0.011 
 
0.19 (0.06, 0.65) 0.008 
Education level 
      
  Illiteracy & elementary 
school 
67 (41.6) -- 
  
-- 
 
  Middle school 59 (36.7) 1.67 (0.95, 2.94) 0.074 
 
1.23 (0.62, 2.44) 0.561 
  High school & above 35 (21.7) 1.99 (0.99, 4.00) 0.055 
 
1.53 (0.62, 3.79) 0.354 
ART site 
      
  Site A 56 (34.8) -- 
  
-- 
 
  Site B 56 (34.8) 1.04 (0.55, 1.96) 0.914 
 
0.97 (0.32, 2.96) 0.962 
  Site C 49 (30.4) 0.55 (0.30, 1.01) 0.053 
 
0.28 (0.10, 0.76) 0.012 
Time of ART initiation 
      
  2015 85 (52.8) 1.56 (0.95, 2.57) 0.081 
 
1.78 (0.98, 3.25) 0.059 
  2016 76 (47.2) -- 
  
-- 
 
Interval between HIV 
diagnosis and ART initiation       
  <7 days 72 (44.7) -- 
  
-- 
 
  7 days - 1 month 29 (18.0) 0.58 (0.30, 1.13) 0.110 
 
0.50 (0.23, 1.11) 0.087 
  1 month - 1 year 37 (23.0) 0.97 (0.49, 1.93) 0.939 
 
0.77 (0.34, 1.76) 0.534 
  >1 year 23 (14.3) 0.50 (0.25, 1.01) 0.053 
 
0.24 (0.10, 0.60) 0.002 
CD4 cell count/μL at ART 
initiation       
  <200 36 (22.4) -- 
  
-- 
 
  200-350 57 (35.4) 2.28 (1.18, 4.40) 0.014 
 
3.32 (1.47, 7.53) 0.004 
  350-500 36 (22.4) 1.33 (0.68, 2.63) 0.407 
 
0.92 (0.40, 2.11) 0.874 
  >500 32 (19.9) 2.13 (0.99, 4.60) 0.053 
 
2.90 (1.13, 7.91) 0.028 
Baseline ART regimen 
      
  TDF+3TC+EFV 69 (42.9) -- 
  
-- 
 
  AZT+3TC+EFV 49 (30.4) 0.61 (0.34, 1.08) 0.091 
 
0.78 (0.34, 1.81) 0.567 
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  LPV/r+other drugs 20 (12.4) 1.13 (0.47, 2.73) 0.791 
 
2.59 (0.74, 8,98) 0.135 
  Other combinations 23 (14.3) 0.65 (0.31, 1.36) 0.350 
 
0.57 (0.22, 1.49) 0.247 
Total score of ART/VL 
related knowledge       
  Lower 77 (47.8) 1.14 (0.69, 1.87) 0.615 
 
4.37 (1.85, 10.32) 
<0.00
1 
  Higher 84 (52.2) -- 
  
-- 
 
Current marital status 
      
  Single 48 (30.0) -- 
  
-- 
 
  Married, with an HIV 
negative spouse 
57 (35.6) 1.04 (0.57, 1.88) 0.900 
 
1.06 (0.45, 2.49) 0.895 
  Married, with an HIV 
positive spouse 
55 (34.4) 1.49 (0.79, 2.80) 0.221 
 
1.87 (0.73, 4.82) 0.196 
Living status 
      
  Live alone 36 (22.4) 1.20 (0.67, 2.15) 0.532 
 
0.94 (0.40, 2.24) 0.891 
  Live with a spouse/partner 52 (32.3) 0.97 (0.52, 1.81) 0.915 
 
0.77 (0.38, 1.58) 0.475 
  Live with family members 
(including the spouse/partner) 
73 (45.3) -- 
  
-- 
 
Support from NGOs 
      
  Got much support 68 (42.2) 1.25 (0.69, 2.26) 0.457 
 
2.54 (1.07, 6.02) 0.034 
  Got some support 49 (30.4) 1.40 (0.73, 2.68) 0.307 
 
1.76 (0.75, 4.10) 0.193 
  Never got any support 44 (27.3) --     --   
ART: antiretroviral therapy; TDF: tenofovir; 3TC: lamivudine; EFV: efavirenz; AZT: zidovudine; LPV/r: 
lopinavir/ritonavir; NGO: non-governmental organization; 
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Discussion 
This study is one of the first studies to investigate factors associated with SVS among PLWH in 
rural China. In our study, more than 95% of participants who initiated ART from 2015 to 2016 
had a VL < 200 copies/mL by the end of 2018, and 61.0% of the participants had been at SVS 
status for at least 18 months. Patients who had taken the initiative to ask about VL testing results 
were significantly more likely to achieve SVS. In addition, some important factors associated 
with SVS were also identified, which could be helpful to add new evidence for current ART 
policy and to make new policies on improving ART service in rural China. 
 
Most participants in the three study sites were not been informed of their VL testing results until 
the next routine follow-up visits, which were generally 3 to 4 months after VL blood collection. 
More than half (58.3%, n=154) of participants had ever taken the initiative to ask about VL 
testing results before the patient notification. After controlling all potential confounders and 
potential effect modifiers, proactively asking about VL testing results became a much stronger 
predictor of SVS (Table 4.5). PLWH who had asked about VL testing results might have positive 
attitudes towards ART and feel less HIV-related stigma. Patients with positive attitudes towards 
ART could be more concerned about their ART response and more likely to communicate with 
healthcare providers to ask about testing results. Studies conducted in African countries and a 
systematic review considering Asian populations
27–29
 reported that PLWH with positive attitudes 
towards ART had better treatment adherence, which could directly improve their virological 
outcomes. In addition, previous studies
30–33
 reported that perceived stigma among PLWH was 
associated with the delayed presentation in care and less usage of healthcare service, leading to 
diminished ART adherence and adverse health outcomes. However, it also should be pointed out 
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that PLWH with unsuppressed VL might be informed earlier than others, which would reduce 
the likelihood that they would feel a need to inquire about the results.  
 
Participants who were at a higher level of VL-related knowledge were more likely to proactively 
ask about VL testing results, and an obvious dose-response relationship was observed in our 
study population (Ptrend<0.001). A qualitative study
34
 in rural African settings showed that a lack 
of HIV/ART-related knowledge could challenge the patient-provider relationship, which reduced 
patients’ willingness to communicate with healthcare providers. However, it is still controversial 
whether HIV/ART-related knowledge is positively associated with good treatment outcomes. 
Some previous studies
27,35–37
 reported a high level of HIV/ART-related knowledge was 
associated with better ART adherence, which directly contributed to SVS. Whereas, our study 
reported the opposite result, which indicated participants with better VL-related knowledge were 
less likely to achieve SVS. Among the 154 participants who had ever actively asked about VL 
testing results, the VL-related knowledge was not associated with SVS in both univariate and 
multivariate analyses. This result was supported by a qualitative study conducted in the United 
States
38, which indicated that most PLWH just simply followed the physicians’ instruction, and 
good knowledge of HIV and ART was not associated with good treatment adherence. 
Noticeably, among the 110 participants who had never asked about VL results, people with 
higher VL-related knowledge score were significantly less likely to have SVS (aOR=0.11, 95% 
CI=0.02-0.57). A possible explanation of this finding was that PLWH who had better HIV/ART-
related knowledge were more likely at higher socioeconomic status (SES) and thus to have 
higher levels of perceived stigma towards HIV infection, especially in the rural settings
39,40
, so 
that the ART adherence and outcomes might be adversely affected
31,41,42
. Additionally, it was 
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also possible that patients who had suboptimal virological outcomes were more likely to receive 
patient education, which helped them get a higher score for VL-related knowledge in the survey 
which did not translate to a higher probability of achieving SVS. 
 
The current standard ART practice in China does not require the VL test at baseline, thus the 
baseline CD4 cell count is regarded as the important predictor of ART response
14,43,44
. Our study 
suggested that participants with a baseline CD4 cell count > 200/μL at ART initiation were more 
likely to achieve SVS, but no dose-response was observed. This finding was supported by some 
previous studies
45,46, which reported baseline CD4 cell count lower than 200/μL was 
significantly associated with virologic failure. In each of the three study sites, there were one to 
three NGO staff assisting the physicians in daily work and providing peer support to patients. A 
total of 110 participants reported they had “got much support” from the NGO staff, and they 
were more likely to achieve SVS compared to those who had “never got any support” from local 
NGOs. Studies
47,48
 conducted in LMICs demonstrated the local NGO staff could provide service 
that was very helpful to improve PLWH’s adherence and ART outcomes. In addition, there was 
a trend that the participants who initiated ART in 2015 were more likely to achieve SVS by the 
end of 2018 compared to those who initiated ART in 2016, although the association was not 
statistically significant in our main analyses (SVS for 18 months: aOR=1.78, 95% CI=0.98, 3.25; 
SVS for 12 months: aOR=1.91, 95% CI=1.03, 3.46). Generally, PLWH who remained in clinical 
care for a longer time would have better virological outcomes. 
 
A new ART policy requiring immediate ART regardless of CD4 count was implemented in the 
second half of 2016 in China and gradually scaled up to the whole country
14,49
. Since only 
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PLWH who initiated ART in 2015 and 2016 were included in our study, the majority of 
participants still used the old ART initiating criteria, which required initiating ART after CD4 
cell count dropped to < 500/μL. In our study, a total of 62.7% of the participants initiated ART 
within 1 month after HIV diagnosis. Participants who initiated ART later than 1 year after HIV 
diagnosis were significantly less likely to achieve SVS. A nationwide cohort study conducted in 
China
9
 also reported that delayed ART initiation could significantly increase the risk of treatment 
failure. Another finding in our study was that participants initiated ART after the age of 60 years 
were less likely to achieve SVS compared to those who initiated ART at the age of 18 to 30. 
Previous cohort studies
9,50
 conducted in Asian populations indicated that older age could be an 
independent predictor for suboptimal ART outcomes. In addition, participants recruited from 
ART Site C were less likely to achieve SVS. About one-third of participants from Site C were 
recruited from patient education meetings, which tended to recruit PLWH who had suboptimal 
adherence and VL results. Hence, it was possible that the overall SVS rate (%) among 
participants in Site C was influenced. 
 
There are some limitations to our study. First, the recall bias could exist since the information 
about previous VL testing experience was collected based on participants’ recollection and might 
have caused non-differential misclassification of the study exposure. To minimize the influences 
of the recall bias, we didn’t recruit PLWH who initiated ART before 2015. Second, because the 
data on the temporal relationships between the exposure and other covariates (e.g. VL-related 
knowledge) and the outcome were collected cross-sectionally, causal relationships between these 
factors and SVS could not be determined. Third, there might be a selection bias in our study. The 
total numbers of patients who were screened for eligibility and invited to participate in the 
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survey were unknown, so that an accurate participation rate could not be calculated. However, 
the participants' recruitment was completed prior to VL-related data extraction, so the 
recruitment was not influenced by the SVS status. In addition, as shown in Supplement Table 
4.2, most of the basic demographic and clinical characteristics were comparable between the 
participants and those who were eligible but didn’t participate in the survey. Therefore, the 
participants in the survey could have certain representativeness of the whole eligible population. 
Fourth, only the PLWH who were still alive and retained in care during the survey-period could 
be recruited in the study, so that a survival bias might exist and the rates (%) of viral suppression 
and SVS were overestimated. Finally, since we only selected Wenshan as the study location, the 
generalizability of the findings in our study might be limited.  
 
Good virological outcomes of ART among PLWH retaining in care were observed in our study. 
In resource-limited settings where ART service has not been fully developed, it is crucial to 
encourage patients to actively communicate with healthcare providers and raise patients’ 
concerns of ART and VL testing. HIV/ART-related knowledge is not sufficient for optimal 
treatment outcomes. Patients who are older than 60, have baseline CD4 counts < 200/μL and 
initiate ART later than 1 year after HIV diagnosis need to be targeted. The local NGOs should be 
recruited to assist in the support of ART services as a strategy to increase SVS. To further 
investigate factors contributing to better virological outcomes among rural PLWH, larger-scaled 
follow-up studies covering more regions and participants are needed in the future. 
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Supplement Table 4.1 Factors associated with sustained viral suppression for 12 months by 
logistic regression modeling, N=264 
Variable 
Sustained 
viral 
suppression 
(n%) 
Univariate model 
 
Multivariate model 
cOR (95% CI) P-value   aOR (95% CI) 
P-
value 
Overall 164 (100) 
     
Ever asked about VL testing 
results before patient 
notification 
      
  Yes 104 (63.4) 1.73 (1.05, 2.87) 0.033 
 
2.76 (1.37, 5.55) 0.004 
  No 60 (36.6) -- 
  
-- 
 
Gender 
      
  Male 94 (57.3) 0.93 (0.56, 1.55) 0.789 
 
1.10 (0.57, 2.13) 0.772 
  Female 70 (42.7) -- 
  
-- 
 
Age at ART initiation, years 
      
  18-30 36 (22.0) -- 
  
-- 
 
  30-45 69 (42.1) 0.75 (0.37, 1.51) 0.419 
 
0.88 (0.38, 2.06) 0.770 
  45-60 46 (28.0) 0.79 (0.37, 1.68) 0.536 
 
1.25 (0.48, 3.26) 0.654 
  >60 13 (7.9) 0.34 (0.13, 0.86) 0.023 
 
0.25 (0.08, 0.84) 0.025 
Education level 
      
  Illiteracy & elementary 
school 
70 (42.7) -- 
  
-- 
 
  Middle school 59 (36.0) 1.80 (0.89, 2.63) 0.100 
 
1.19 (0.56, 2.21) 0.750 
  High school & above 35 (21.3) 1.52 (0.86, 2.67) 0.148 
 
1.41 (0.58, 3.45) 0.452 
ART site 
      
  Site A 56 (34.2) -- 
  
-- 
 
  Site B 56 (34.2) 1.04 (0.55, 1.96) 0.914 
 
0.96 (0.32, 2.87) 0.936 
  Site C 52 (31.7) 0.63 (0.34, 1.15) 0.129 
 
0.36 (0.14, 0.96) 0.042 
Time of ART initiation 
      
  2015 87 (53.1) 1.63 (0.98, 2.69) 0.058 
 
1.91 (1.05, 3.46) 0.034 
  2016 77 (46.9) -- 
  
-- 
 
Interval between HIV 
diagnosis and ART 
initiation 
      
  <7 days 74 (45.1) -- 
  
-- 
 
  7 days - 1 month 30 (18.3) 0.57 (0.29, 1.13) 0.106 
 
0.53 (0.24, 1.17) 0.115 
  1 month - 1 year 37 (22.6) 0.90 (0.45, 1.78) 0.751 
 
0.72 (0.31, 1.63) 0.426 
  >1 year 23 (14.0) 0.46 (0.23, 0.93) 0.031 
 
0.25 (0.10, 0.61) 0.002 
CD4 cell count/μL at ART 
initiation       
  <200 38 (23.2) -- 
  
-- 
 
  200-350 57 (34.8) 2.04 (1.06, 3.95) 0.034 
 
2.87 (1.27, 6.45) 0.011 
  350-500 37 (22.6) 1.27 (0.64, 2.52) 0.488 
 
0.90 (0.39, 2.05) 0.801 
  >500 32 (19.5) 1.91 (0.89, 4.12) 0.099 
 
2.62 (1.00, 6.84) 0.049 
Baseline ART regimen 
      
  TDF+3TC+EFV 71 (43.3) -- 
  
-- 
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  AZT+3TC+EFV 50 (30.5) 0.58 (0.32, 1.04) 0.069 
 
0.62 (0.27, 1.42) 0.258 
  LPV/r+other drugs 20 (12.2) 1.03 (0.43, 2.51) 0.943 
 
2.10 (0.62, 7.13) 0.234 
  Other combinations 23 (14.0) 0.59 (0.28, 1.25) 0.169 
 
0.46 (0.18, 1.19) 0.109 
Total score of ART/VL 
related knowledge       
  Lower 79 (48.2) 1.18 (0.72, 1.95) 0.510 
 
4.43 (1.89, 10.37) <0.001 
  Higher 85 (51.8) -- 
  
-- 
 
Current marital status 
      
  Single 50 (30.7) -- 
  
-- 
 
  Married, with an HIV 
negative spouse 
57 (35.0) 0.94 (0.52, 1.71) 0.840 
 
0.99 (0.42, 2.30) 0.976 
  Married, with an HIV 
positive spouse 
56 (34.3) 1.42 (0.75, 2.70) 0.281 
 
1.85 (0.73, 4.75) 0.198 
Living status 
      
  Live alone 38 (23.2) 1.27 (0.71, 2.28) 0.421 
 
1.12 (0.47, 2.64) 0.799 
  Live with a spouse/partner 53 (32.3) 1.11 (0.59, 2.09) 0.748 
 
0.83 (0.41, 1.69) 0.607 
  Live with family members 
(including the spouse/partner) 
73 (44.5) -- 
  
-- 
 
Supports from NGOs 
      
  Got much supports 70 (42.7) 1.28 (0.71, 2.32) 0.410 
 
2.50 (1.07, 5.86) 0.035 
  Got some supports 49 (29.9) 1.33 (0.70, 2.55) 0.389 
 
1.72 (0.74, 3.96) 0.205 
  Never got any support 45 (27.4) --     --   
ART: antiretroviral therapy; TDF: tenofovir; 3TC: lamivudine; EFV: efavirenz; AZT: zidovudine; LPV/r: 
lopinavir/ritonavir; NGO: non-governmental organization; 
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Supplement Table 4.2 The comparison of demographic and clinical characteristics for eligible 
PLWH who participated in and didn’t participate in the survey 
Characteristics 
Total eligible 
PLWH (n%) 
PLWH 
participated 
survey (n%) 
PLWH not 
participated 
survey (n%) 
P-value 
Overall 815 (100) 264 (100) 551 (100) 
 
Gender 
    
  Male 491 (60) 153 (58) 338 (61) 0.355 
  Female 324 (40) 111 (42) 213 (39) 
 
Age at ART initiation, years 
    
  Median (IQR) 41.8 (32.2, 51.4) 41.9 (32.3, 51.9) 41.5 (32.1, 50.6) 0.574 
Education level 
    
  Illiteracy & elementary school 389 (48) 124 (47) 265 (48) 0.171 
  Middle school 295 (36) 89 (34) 206 (38) 
 
  High school & above 127 (16) 50 (19) 77 (14) 
 
Route of HIV transmission 
    
  Heterosexual behaviors 770 (94) 252 (95) 518 (94) 0.398 
  Other 45 (6) 12 (5) 33 (6) 
 
Interval between HIV 
diagnosis and ART initiation     
  Median (IQR), days 14 (5, 173) 13 (5, 161) 14 (6, 182) 0.224 
CD4 cell count/μL when ART 
initiated     
  Median (IQR) 316 (199, 447) 321 (210, 452) 314 (193, 443) 0.620 
Baseline ART regimen 
    
  TDF+3TC+EFV 278 (34.1) 104 (39.4) 174 (31.6) 0.008 
  AZT+3TC+EFV 315 (38.7) 90 (34.1) 225 (40.8) 
 
  LPV/r+other drugs 66 (8.1) 29 (11.0) 37 (6.7) 
   Other combinations 156 (19.1) 41 (15.5) 115 (20.9)   
PLWH: people living with HIV, ART: antiretroviral therapy; TDF: tenofovir; 3TC: lamivudine; EFV: 
efavirenz; AZT: zidovudine; LPV/r: lopinavir/ritonavir 
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Chapter 5: Conclusions 
Despite great achievements in HIV/AIDS epidemic control that have been made in China, there 
is still a gap with the 90-90-90 targets. This dissertation focuses on the centralized viral load 
(VL) test in rural China. Three important but easily-neglected topics throughout the whole 
process of VL testing are respectively investigated in three sub-studies. First, universal access to 
timely VL testing is the foundation of antiretroviral therapy (ART) response evaluation. Second, 
poor efficiency and prolonged turnaround time (TAT) of VL testing greatly reduce the value of 
VL testing. Third, the process of patient notification of VL testing is also associated with ART 
outcomes. To our knowledge, this is one of the first studies specifically targeting the VL testing 
in rural PLWH of China. 
 
Results of the first study show that 58.5% of people living with HIV (PLWH) receiving ART 
underwent their first VL test within the first year of ART. In the rural areas, where the traffic and 
economy are not fully developed, it is highly recommended to decentralize HIV healthcare 
service to remote areas, so that PLWH who are living far away from ART facilities and have 
suboptimal health status are more likely to utilize the ART services. The working burden of rural 
healthcare providers is quite heavy since the physician-patient ratio is low and rural PLWH are 
highly dependent on the healthcare providers. It is important to increase the number of healthcare 
providers and providing them more training opportunities. In addition, the local non-
governmental organizations (NGOs), which provide service and peer support for PLWH in local 
ART sites, can be enhanced to act as an auxiliary method to improve ART uptake and adherence. 
In our study, PLWH who are younger than 30 years and at a low education level need to be 
particularly targeted to improve the VL testing rates.    
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The median TAT among all VL tests conducted in the study sites during 2018 is 54 days (IQR: 
36-92), which is still suboptimal. Challenges to increase the VL testing efficiency exist in each 
process of the centralized VL testing. Both the number of healthcare providers at local ART sites 
and the number of technicians at the VL testing laboratory should be increased. It is suggested to 
strengthen the relevant professional training, improve the laboratory network construction, 
ensure sufficient testing reagent supplies, and improve the ART information system. The 
application of new point of care (POC) VL testing technologies in local ART sites and a flexible 
ART referral system among migrant PLWH should also be explored in rural China. 
 
Good virological outcomes of ART among PLWH retaining in care are observed in the third 
study. By the end of 2018, more than 95% of participants who initiated ART from 2015 to 2016 
had achieved a VL<200 copies/mL, and 61.0% had achieved sustained viral suppression (SVS) 
for at least 18 months. In resource-limited settings where ART service has not been fully 
developed, it is more important to raise patients’ concerns for ART and encourage patients to 
actively communicate with healthcare providers than only imparting the HIV/ART-related 
knowledge. To improve SVS, the local NGOs should be recruited to assist in the support of ART 
services. In addition, PLWH who are older than 60, have baseline CD4 counts < 200/μL, and 
initiate ART later than 1 year after HIV diagnosis are key populations for improving long-term 
virological outcomes. 
 
To achieve the 90-90-90 targets, the local ART facilities, VL testing laboratories, healthcare 
policymakers at all levels of government and the NGOs should collaborate and coordinate their 
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procedures. Larger-scaled follow-up studies covering more regions and participants are needed 
in the future to investigate how to improve ART service among rural PLWH in China. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
